Method for producing cell population containing CD4 single positive helper t cells from pluripotent stem cells
The method of culturing hematopoietic stem cells with specific factors effectively produces CD4 single-positive helper T cells and CD8-positive killer T cells, addressing the scarcity of CD4-positive T cells in cancer immunotherapy and enhancing tumor immunity.
Patent Information
- Application Number
- PCT/JP2024/018570
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-05-21
- Publication Date
- 2024-11-28
AI Technical Summary
Current cancer immunotherapy faces challenges in generating sufficient CD4-positive helper T cells from pluripotent stem cells, which are crucial for effective tumor immunity, as existing methods primarily produce CD8-positive killer T cells and lack efficient production of CD4-positive T cells.
A method involving the culturing of hematopoietic stem cells derived from pluripotent stem cells in the presence of specific T cell differentiation-inducing factors, cell adhesion factors, and Wnt/β-catenin pathway activators to selectively produce CD4 single-positive helper T cells, without the external introduction of the CD4 gene, and to generate a cell population containing both CD4-positive helper T cells and CD8-positive killer T cells.
This method enhances the production of functionally superior CD4 single-positive helper T cells with improved proliferation and tumor-killing effects, enabling effective cancer immunotherapy by increasing the proportion of CD4-positive T cells in the cell population.
Smart Images

Figure JPOXMLDOC01-APPB-I000001 
Figure JPOXMLDOC01-APPB-I000002 
Figure JPOXMLDOC01-APPB-I000003
Abstract
Description
Method for producing a cell population containing CD4 single-positive helper T cells from pluripotent stem cells
[0001] The present invention relates to a method for producing a cell population containing CD4 single-positive helper T cells from pluripotent stem cells (Pluripotent Stem Cells), particularly induced pluripotent stem cells (iPS cells), a pharmaceutical containing the cell population, an agent for killing cells expressing a tumor-associated antigen, and an agent for preventing or treating cancer in a mammal, each containing the cell population, and a method for preventing or treating cancer in a mammal, which comprises administering an effective amount of the cell population.
[0002] In recent years, active research has been conducted on cancer immunotherapy, a new cancer treatment method that eliminates cancer by activating the patient's immune system. In this cancer immunotherapy, T cells that specifically recognize and attack cancer are important. However, the number of T cells that recognize cancer is low in the patient's body. Therefore, research is underway on cancer immunotherapy using genetically modified T cells that express receptors on their cell surface that can specifically recognize cancer antigens or tumor-associated antigens. As such genetically modified T cells, T cells that express chimeric antigen receptors (CARs) and T cell receptors (TCRs) that target specific cancer antigens or tumor-associated antigens have been reported, and these are called CAR-T cells and TCR-T cells, respectively (Patent Documents 1 and 2).
[0003] CAR is a fusion protein consisting of the antigen-recognition portion of an antibody that specifically recognizes a cancer antigen or tumor-associated antigen and an intracellular domain derived from a TCR. CAR-T cells can recognize antigens expressed on the cell surface in a manner that is not restricted by human leukocyte antigens (HLA). For this reason, CAR-T cells are expected to be used in allogeneic transplantation as well as autologous transplantation. TCR is a receptor used by T cells to recognize antigens, and is composed of a dimer of α and β chains, or γ and δ chains. TCR forms a complex with CD3 molecules on the surface of T cells and activates them by recognizing antigen molecules bound to major histocompatibility complex (MHC) molecules.
[0004] T cells are broadly classified into killer T cells, consisting of CD8+ T cells that directly recognize tumors and induce apoptosis, and helper T cells, consisting of CD4+ T cells that enhance the functions of killer T cells and other lymphocytes such as B cells. Cancer immunotherapy has focused on CD8+ T cells, which can directly recognize tumor cells. This is because tumor cells that endogenously express MHC class II molecules are directly targeted by CD4+ T cells, but most tumors do not express MHC class II molecules and are not directly recognized by CD4+ T cells. However, tumor antigens can be captured and cross-presented by tumor stromal cells that express MHC class II molecules (Non-Patent Document 1). Necrotic tumor cells or vesicles released from tumor cells are taken up by stromal cells and primarily enter the classical processing pathway for MHC class II molecules, so it has been speculated that cross-presentation of tumor antigens on MHC class II molecules is more effective than that on MHC class I molecules (Non-Patent Document 2). In most solid tumors, monocytes / macrophages are the most abundant MHC class II molecule-positive cells. Depending on the presence or absence of MHC class II molecules on tumor cells and the CD4+ T cell subset, several different mechanisms of tumor elimination have been proposed (Non-Patent Document 1).
[0005] In cancer immunotherapy using genetically modified T cells, difficulties in securing sufficient numbers of T cells, as well as T cell exhaustion, such as reduced T cell proliferation and impaired immune responses to antigens carried by tumor cells, are obstacles to the effective implementation of cancer immunotherapy. To overcome these obstacles and facilitate cancer immunotherapy, techniques have been reported in which induced pluripotent stem cells (iPS cells), established from antigen-specific T cells isolated from peripheral blood mononuclear cells, are expanded and then differentiated into CD8-positive T cells (Patent Documents 3 and 4 and Non-Patent Documents 3 and 4). These techniques are capable of continuously inducing large numbers of functional T cells from iPS cells, and are therefore thought to be an important foundation for cancer immunotherapy using T cells.
[0006] In cancer immunotherapy using genetically modified T cells expressing tumor-reactive TCRs or CARs, it has been reported that combining the most potent CD4-positive and CD8-positive CAR-expressing T cell subsets can achieve synergistic in vivo antitumor effects (Non-Patent Document 5). Therefore, when inducing functional T cells from iPS cells, it is important to generate not only CD8-positive T cells but also CD4-positive T cells. However, the reported techniques described above produce only CD8-positive T cells from iPS cells, and are unable to generate CD4-positive T cells or long-lived naive T cells. To generate CD4-positive T cells from iPS cells, a method has been reported in which the CD4 gene is introduced into iPS cell-induced T cells and the cells are cultured in a culture medium containing interleukin-2 and interleukin-15 (Patent Document 5). A method has also been reported in which iPS cells are cultured in an artificial thymic organ (ATO) to generate CD4-positive T cells (Non-Patent Document 6), but the efficiency of CD4-positive T cell generation is low.
[0007] International Publication No. 2013 / 070468 Pamphlet International Publication No. 2015 / 173112 Pamphlet International Publication No. 2011 / 096482 Pamphlet International Publication No. 2018 / 135646 Pamphlet International Publication No. 2018 / 168829 Pamphlet
[0008] Poncette1 L, et al.The role of CD4 T cells in rejection of solid tumors. Curr. Opin. Immunol. 2022; 74:18-24.Blum JS, et al. Pathways of antigen processing. Ann. Rev. Immunol. 2013: 31:443-473.Nishimura T, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013; 12:114-126.Minagawa A, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell. 2018; 23:850-858.Sommermeyer D, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016; 30:492-500. Montel-Hagen A, et al. Organoid-induced differentiation of conventional T cells from human pluripotent stem cells. Cell Stem Cell. 2019; 24:376-389.
[0009] Current cancer immunotherapy using autologous transplantation of CAR-T cells has shown excellent clinical efficacy. This is because CAR is introduced not only into killer T cells in the peripheral blood but also into helper T cells, which then participate in the immune response. However, in order to perform stable and effective cancer immunotherapy without relying on autologous cells, it is necessary to stably generate helper T cells from pluripotent stem cells.
[0010] An object of the present invention is to provide a method for efficiently producing a cell population containing functionally superior CD4 single-positive helper T cells from pluripotent stem cells. Another object of the present invention is to provide a pharmaceutical containing the cell population produced by the method, an agent for killing cells expressing tumor-associated antigens, and an agent for preventing or treating cancer in a mammal, as well as a method for preventing or treating cancer in a mammal, comprising administering an effective amount of the cell population produced by the method.
[0011] The present inventors discovered that CD4 single-positive helper T cells can be efficiently produced by selecting whether or not to use a T cell differentiation-inducing factor and a cell adhesion factor for each step in the process of inducing differentiation of pluripotent stem cells, and thus completed the present invention.
[0012] The present inventors further discovered that CD4 single-positive helper T cells can be produced by culturing the cells using a Wnt pathway activator in the step of inducing differentiation of pluripotent stem cells, and selecting whether or not to use a T cell differentiation-inducing factor, a cell adhesion factor, and an anti-CD3 antibody for each step, and thus completed the present invention.
[0013] That is, the present invention provides the following: [1] A method for producing a cell population containing CD4 single-positive, CD8-negative helper T cells, comprising: (1) a step of culturing hematopoietic stem cells, differentiation-induced from pluripotent stem cells, in the presence of a T cell differentiation inducer; (2) a step of culturing the cells obtained in step (1) in the presence of a T cell differentiation inducer and a cell adhesion factor; and (3) a step of culturing the cells obtained in step (2) in the presence of a cell adhesion factor but in the absence of a T cell differentiation inducer. [2] The method described in [1], wherein the cell cultures of steps (1), (2), and (3) are performed in the presence of a Wnt / β-catenin pathway activator. [3] The method described in [1] or [2], further comprising a step of confirming that the cells obtained in step (1) contain CD3-, CD1a-, and CD5-positive precursor T cells. [4] The method described in [1] or [2], further comprising a step of confirming that the cells obtained in step (2) contain CD3-positive and CD4 / CD8 double-positive T cells. [5] The method of [4], wherein the CD3-positive and CD4 / CD8-double-positive T cells are further CD5- and CD1a-positive. [6] The method of [1] or [2], wherein the cells obtained in step (3) are mature helper T cells that are CD1a- and CD8-negative and CD5-positive and CD4-single-positive, or a mixture of the mature helper T cells and mature killer T cells that are CD5- and CD8-positive and CD1a- and CD4-negative. [7] The method of [1] or [2], further comprising a step of confirming that the cells obtained in step (3) contain T cells that highly express CD28. [8] The method of [7], wherein the CD28 expression level of the T cells that highly express CD28 is equivalent to the CD28 expression level of T cells present in human peripheral blood.[9] A method for producing a cell population containing CD4 single-positive, CD8-negative helper T cells, comprising: (1) a step of culturing hematopoietic stem cells induced to differentiate from pluripotent stem cells in the presence of a T cell differentiation inducer and a Wnt / β-catenin pathway activator; (2) a step of culturing the cells obtained in step (1) in the presence of a cell adhesion factor, a Wnt pathway activator, and an anti-CD3 antibody, but in the absence of the T cell differentiation inducer; and (3) a step of culturing the cells obtained in step (2) in the presence of a cell adhesion factor and a Wnt pathway activator, but in the absence of the T cell differentiation inducer and the anti-CD3 antibody.
[10] The method according to [9], wherein the cells obtained in step (3) are a mixture of mature helper T cells that are CD1a and CD8 negative, CD5 positive, and CD4 single-positive, and mature killer T cells that are CD5 and CD8 positive, and CD1a and CD4 negative.
[11] The method according to [1] or [9], wherein the T cell differentiation factor is a Notch ligand.
[12] The method according to
[11] , wherein the Notch ligand is DLL4 or DLL4-Fc.
[13] The method according to [1] or [9], wherein the cell adhesion factor is fibronectin or a fragment thereof, or RetroNectin (registered trademark).
[14] The method according to [2] or [9], wherein the Wnt pathway activator is a GSK-3 inhibitor.
[15] The method according to
[14] , wherein the GSK-3 inhibitor is CHIR-99021.
[16] The method according to [1] or [9], wherein the T cell differentiation factor and the cell adhesion factor are present by coating a cell culture substrate.
[17] The method according to
[16] , wherein the cell culture substrate is cell culture beads or a cell culture plate.
[18] The method according to [1] or [2], wherein the cell culture in steps (1) and (2) is performed in the presence of IL-7 and FLT3L.
[19] The method according to [1] or [2], wherein the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, and an SDF-1α and / or p38 inhibitor.
[20] The method according to [1] or [2], wherein the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, SDF-1α, and a p38 inhibitor.
[21] The method according to [1] or [2], wherein the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, SDF-1α, a p38 inhibitor, and SCF.
[22] The method according to [1] or [2], wherein the cell culture in step (3) is carried out in the presence of IL-7.
[23] The method according to [1] or [2], wherein the cell culture in step (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, and SDF-1α and / or a p38 inhibitor.
[24] The method according to [1] or [2], wherein the cell culture in step (3) is carried out in the presence of IL-7, SDF-1α, and a p38 inhibitor.
[25] The method according to [1] or [2], wherein the cell culture in step (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, SDF-1α, a p38 inhibitor, and SCF.
[26] The method according to [1] or [2], wherein the cell culture in steps (1) and (2) is carried out while maintaining the cell density at subconfluence.
[27] The method according to [9], wherein the cell culture in step (1) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, SDF-1α, a p38 inhibitor, SCF, and TPO.
[28] The method according to [9], wherein the cell culture in steps (2) and (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, SDF-1α, and a p38 inhibitor.
[29] The method according to [1] or [9], wherein the pluripotent stem cells are human iPS cells.
[30] The method according to
[29] , wherein the human iPS cells are human peripheral blood mononuclear cells from which B cells and T cells have been removed, or iPS cells obtained by reprogramming T cells.
[31] A pharmaceutical comprising the cell population produced by the method according to [1] or [9].
[32] The pharmaceutical according to
[31] , for use in the prevention or treatment of cancer.
[33] An agent for killing cells expressing a tumor-associated antigen, comprising the cell population produced by the method according to [1] or [9].
[34] A method for the prevention or treatment of cancer in a mammal, comprising administering to the mammal an effective amount of the cell population produced by the method according to [1] or [9].
[35] A method for preventing or treating cancer in a mammal, comprising administering to the mammal an effective amount of the medicament according to
[31] .
[36] A method for preventing or treating cancer in a mammal, comprising administering to the mammal an effective amount of the killing agent according to
[33] .
[37] A preventive or therapeutic agent for cancer in a mammal, comprising a cell population produced by the method according to [1] or [9].
[38] Cells produced by the method according to [1] or [9] for use in the prevention or treatment of cancer.
[39] Cells produced by the method according to [1] or [9] for producing a preventive or therapeutic agent for cancer.
[0014] In the present specification, the method described in [1] is referred to as the first method, and the method described in [9] is referred to as the second method.
[0015] CD4 single-positive helper T cells are necessary for enhancing tumor immunity, but based on previously reported techniques, T cells produced from pluripotent stem cells are mainly CD8 single-positive killer T cells, and CD4 single-positive helper T cells cannot be efficiently produced. According to the present invention, a cell population containing CD4 single-positive helper T cells can be produced without exogenous CD4 gene introduction by culturing hematopoietic stem cells induced to differentiate from pluripotent stem cells in the presence of a T cell differentiation inducer, then in the presence of a T cell differentiation inducer and a cell adhesion factor, and finally in the presence of a cell adhesion factor but in the absence of a T cell differentiation inducer. Furthermore, according to the present invention, a cell population containing CD4 single-positive helper T cells and CD8 positive killer T cells can be produced. Furthermore, the proportion of CD4 single-positive helper T cells in the cell population can be increased by culturing the hematopoietic stem cells in the presence of a Wnt / β-catenin pathway activator throughout the entire culture period.
[0016] Furthermore, according to the present invention, hematopoietic stem cells induced to differentiate from pluripotent stem cells are cultured in the presence of a T cell differentiation inducer and a Wnt / β-catenin pathway activator, then in the presence of a cell adhesion factor, a Wnt pathway activator, and an anti-CD3 antibody, but in the absence of a T cell differentiation inducer, and finally in the presence of a cell adhesion factor and a Wnt pathway activator, but in the absence of a T cell differentiation inducer and an anti-CD3 antibody, thereby producing a cell population containing CD4 single-positive helper T cells and CD8 positive killer T cells.
[0017] The CD4 single-positive helper T cells prepared by the method of the present invention have superior cell proliferation properties and superior cancer cell-killing and in vivo tumor-suppressing activities compared to CD8 single-positive killer T cells. A pharmaceutical containing a cell population containing the CD4 single-positive helper T cells prepared by the method of the present invention, or an agent for killing cells expressing a tumor-associated antigen, is useful for the prevention or treatment of cancer.
[0018] 1 shows the results of a flow cytometric analysis of the effects of coating cell culture plates with DLL4-Fc and RetroNectin in each step on the generation of CD4 single-positive helper T cells from iPS cells. FIG. 2 shows the results of a flow cytometric analysis of the effects of coating cell culture plates with DLL4-Fc and RetroNectin in step (3) on the generation of CD4 single-positive helper T cells from iPS cells. FIG. 3 shows a comparison of the coating conditions in step (3) with the amount of CD4 single-positive helper T cells generated from iPS cells. FIG. 4 shows the results of a flow cytometric analysis of the effects of coating cell culture plates with DLL4-Fc and RetroNectin in steps (1) and (2) on the generation of CD4 single-positive helper T cells from iPS cells. FIG. 5 shows a comparison of the coating conditions in steps (1) and (2) with the amount of CD4 single-positive helper T cells generated from iPS cells.
[0033] Figure 1 shows the effect of a Wnt pathway activator (CHIR-99021) on the generation of CD4 single-positive helper T cells from iPS cells. Figure 2 shows the results of flow cytometry analysis of CD40L expression upon TCR stimulation of CD4 single-positive helper T cells matured from iPS cells by DLL4-Fc / retroNectin switching treatment and anti-CD3 antibody treatment in the coating of cell culture plates. Figure 3 shows the results of flow cytometry analysis of CD40L expression upon TCR stimulation of CD4 single-positive helper T cells and CD8 single-positive killer T cells that have undergone different maturation processes. Figure 4 shows the results of TaqMan qPCR analysis of Thpok and PLZF expression in CD4 single-positive helper T cells and CD8 single-positive killer T cells generated from iPS cells by DLL4-Fc / retroNectin switching in the coating of cell culture plates, and compares the results with those in primary T cells of the adaptive immune system obtained from peripheral blood.Figure 1 shows the results of measuring Thpok and Runx3 expression in CD4 single-positive helper T cells and CD8 single-positive killer T cells that have undergone different maturation processes, measured by TaqMan qPCR. Figure 2 shows the results of measuring the proliferation of CD4 single-positive helper T cells and CD8 single-positive killer T cells that have undergone different maturation processes. Figure 3 shows the results of flow cytometry analysis of naive markers (CD28) and adaptive immune markers (CD2 and CD5) expressed by CD4 single-positive helper T cells and CD8 single-positive killer T cells generated from iPS cells by DLL4-Fc / retroNectin switching in the coating of cell culture plates after feeder-free expansion, and compares the results with those of the T cells before expansion and fresh human peripheral blood mononuclear cells. Figure 1 shows the results of retroviral gene transfer of anti-CD19 CAR (anti-CD19 CAR-IRES-EGFR) into a cell population containing CD4 single-positive helper T cells and CD8 single-positive killer T cells, which were produced from iPS cells by DLL4-Fc / retroNectin switching in the coating of cell culture plates, and analyzing the EGFR expression of the resulting cells by flow cytometry. Figure 1 shows the results of measuring the amounts of cytokines (IFN-γ, IL-2, and TNFα) in the culture supernatant after 24 hours of co-culture of CD4 single-positive helper T cells and CD8 single-positive killer T cells, which were produced from iPS cells by DLL4-Fc / retroNectin switching in the coating of cell culture plates and had been transfected with anti-CD19 CAR-IRES-EGFR, with the CD19-positive human pre-B cell leukemia cell line Nalm6. FIG. 1 shows the killing activity of CD4 single-positive helper T cells and CD8 single-positive killer T cells generated from iPS cells by DLL4-Fc / retroNectin switching in the coating of cell culture plates against the human pre-B cell leukemia cell line Nalm6.1 shows the effects of IL-7 and IL-15 on the killing activity of CD4 single-positive helper T cells and CD8 single-positive killer T cells generated from iPS cells by DLL4-Fc / retroNectin switching in the coating of cell culture plates against the human pre-B cell leukemia cell line Nalm6. 2 shows the results of measuring the cytotoxic activity of CD4 single-positive helper T cells and CD8 single-positive killer T cells generated from iPS cells by DLL4-Fc / retroNectin switching in the coating of cell culture plates, T cells generated from iPS cells generated by artificial thymus organ (ATO) culture, and primary T cells derived from healthy individuals after introducing anti-CD19 CAR into them. 17A and 17B show the results of measuring the cytotoxic activity against the CD19-negative human leukemia cell line K562 after introducing anti-CD19 CAR into CD4 single-positive helper T cells and CD8 single-positive killer T cells generated from iPS cells by DLL4-Fc / retroNectin switching in the coating of cell culture plates, T cells generated from iPS cells generated by artificial thymus organ (ATO) culture, and primary T cells derived from healthy individuals. 17B shows the results of measuring the effect of intravenous injection of CD4 single-positive helper T cells and CD8 single-positive killer T cells generated from iPS cells by DLL4-Fc / retroNectin switching in the coating of cell culture plates into NSG mice transplanted with the human pre-B cell leukemia cell line Nalm6 on the pharmacokinetics of the Nalm6 in the mice by in vivo imaging using luciferase luminescence. 17C shows the Kaplan-Meier survival curves for the NSG mice described in FIG. 17A. FIG. 1 shows the results of flow cytometry analysis of CD4 single-positive helper T cells generated from hematopoietic stem cells derived from human iPS cells in the presence of a Wnt pathway activator (CHIR-99021).18A shows the results of flow cytometry analysis of the expression of CD5, TCRα chain / β chain, and CD1a in the CD4 single-positive T cell subset shown in Fig. 18A. This figure shows the results of flow cytometry analysis of the effect of a Wnt pathway activator (CHIR-99021) on the generation of CD4 single-positive helper T cells from hematopoietic stem cells derived from iPS cells. This figure shows the percentage and cell yield of mature CD8 single-positive killer T cells in T cells produced from hematopoietic stem cells derived from iPS cells in the presence of a Wnt pathway activator (CHIR-99021). This figure shows the percentage and cell yield of mature CD4 single-positive helper T cells in T cells produced from hematopoietic stem cells derived from iPS cells in the presence of a Wnt pathway activator (CHIR-99021). Figure 1 shows the results of flow cytometric analysis of CD4 and CD8 expression in mature T cells generated from hematopoietic stem cells derived from iPS cells in the presence of a Wnt pathway activator (CHIR-99021), and the results of flow cytometric analysis of CD4 and CD8 expression in CD4 and CD8 single-positive T cells after flow cytometric sorting and subsequent expansion using anti-CD3 and anti-CD28 antibody-bound beads. Figure 2 shows the results of flow cytometric analysis of CD40L expression in CD4 single-positive helper T cells generated from hematopoietic stem cells derived from iPS cells in the presence of a Wnt pathway activator (CHIR-99021), stimulated with or without anti-CD3 antibody (OKT3). FIG. 1 shows the results of measuring cytokines (IFN-γ and IL-2) produced by stimulating CD4 single-positive helper T cells and CD8 single-positive killer T cells, which were generated from hematopoietic stem cells derived from human iPS cells in the presence of a Wnt pathway activator (CHIR-99021), with PMA and ionomycin in the presence of momensin.Figure 1 shows the results of retroviral gene transfer of anti-CD19 CAR (anti-CD19 CAR-4-1BB-CD3zeta) into CD4 single-positive helper T cells and CD8 single-positive killer T cells prepared from hematopoietic stem cells derived from human iPS cells in the presence of a Wnt pathway activator (CHIR-99021), followed by flow cytometry analysis of the expression of anti-CD19 CAR in the resulting cells. Figure 1 shows the results of measurement of the cytotoxic activity against the CD19-positive human pre-B cell leukemia cell line Nalm6 after transfection of anti-CD19 CAR (anti-CD19 CAR-4-1BB-CD3zeta) into CD4 single-positive helper T cells and CD8 single-positive killer T cells prepared from hematopoietic stem cells derived from human iPS cells in the presence of a Wnt pathway activator (CHIR-99021).
[0019] The present invention provides a method for producing a cell population containing CD4 single-positive, CD8-negative helper T cells. The first method of the present invention comprises the steps of: (1) culturing hematopoietic stem cells, differentiation of which has been induced from pluripotent stem cells, in the presence of a T cell differentiation-inducing factor; (2) culturing the cells obtained in step (1) in the presence of a T cell differentiation-inducing factor and a cell adhesion factor; and (3) culturing the cells obtained in step (2) in the presence of the cell adhesion factor but in the absence of the T cell differentiation-inducing factor. The second method of the present invention comprises the steps of: (1) culturing hematopoietic stem cells, differentiation of which has been induced from pluripotent stem cells, in the presence of a T cell differentiation inducer and a Wnt / β-catenin pathway activator; (2) culturing the cells obtained in step (1) in the presence of a cell adhesion factor, a Wnt pathway activator, and an anti-CD3 antibody, but in the absence of a T cell differentiation inducer; and (3) culturing the cells obtained in step (2) in the presence of a cell adhesion factor and a Wnt pathway activator, but in the absence of a T cell differentiation inducer and an anti-CD3 antibody.
[0020] [Pluripotent Stem Cells] In the present invention, pluripotent stem cells are stem cells that have both the ability to grow almost infinitely (self-proliferation) and the ability to differentiate into almost all cells that make up an individual (multipotency). Pluripotent stem cells include, but are not limited to, embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), embryonic germ stem cells (EG cells), multipotent germline stem cells (mGS cells), embryonic stem cells derived from cloned embryos obtained by nuclear transfer (nuclear transfer embryonic stem cells (ntES cells)), and pluripotent stem cells isolated from fibroblasts, bone marrow mesenchymal cells, etc. (multi-lineage differentiating stress enduring cells (Muse cells)). iPS cells may also be used as pluripotent stem cells, as they do not require the destruction of embryos or eggs and have high differentiation potential.
[0021] [Generation of iPS Cells] iPS cells are generated by reprogramming mammalian somatic cells. Examples of mammals include humans, monkeys, pigs, dogs, cats, rats, and mice, with humans being preferred. The somatic cells can be, but are not limited to, cells isolated from peripheral blood. In one embodiment of the present invention, the somatic cells are peripheral blood mononuclear cells (PBMCs) or T cells depleted of B cells and T cells. B- and T-cell-depleted PBMCs may be obtained by isolating PBMCs from whole blood using a mononuclear cell separation solution, followed by removal of B cells and T cells using surface antigens expressed on the PBMCs. Examples of mononuclear cell separation solutions include Lymphoprep®. B and T cells can be removed from PBMCs using antibodies against B cell surface antigens CD19, CD20, CD22, or the B cell receptor, and T cell surface antigens CD3, CD4, or CD8, using flow cytometry or magnetic beads such as MACS® beads. T cells can be isolated from peripheral blood by negative sorting to remove non-T cells such as monocytes, neutrophils, eosinophils, B cells, stem cells, dendritic cells, NK (natural killer) cells, and erythrocytes using specific antibodies against surface antigens (e.g., CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, and CD234a (Glycophorin A)) present on these cells. T cells may also be isolated from peripheral blood mononuclear cells by positive selection.
[0022] The source of T cells is preferably, but not limited to, peripheral blood because of its minimal invasiveness. Other sources include cancer tissue, tumor tissue, or other tissues, umbilical cord blood, lymph, tissue fluid (interstitial fluid, intercellular fluid, and interstitial fluid), body cavity fluid (ascites, pleural effusion, pericardial fluid, cerebrospinal fluid, synovial fluid, and aqueous humor), nasal discharge, urinary pleural cavity, peritoneal cavity, cranial cavity, or spinal canal effusion (pleural effusion, ascites, etc.). Examples of the cancer tissue or tumor tissue include tissues derived from ovarian cancer, hepatoblastoma, hepatocellular carcinoma, gastric cancer, esophageal cancer, pancreatic cancer, renal cell carcinoma, breast cancer, malignant melanoma, non-small cell lung cancer, cervical cancer, glioblastoma, prostate cancer, neuroblastoma, chronic lymphocytic leukemia, papillary thyroid cancer, colon cancer, head and neck cancer, brain tumor, multiple myeloma, and B-cell non-Hodgkin's lymphoma.
[0023] Methods for producing iPS cells are known in the art (see, for example, Takahashi K, Yamanaka S. Cell. 2006; 126:663-676; Takahashi K, et al. Cell. 2007; 131:861-872; Nakagawa M, et al. Nat Biotechnol. 2008; 26:101-106.) In one embodiment of the present invention, iPS cells can be induced by introducing a cell reprogramming factor into peripheral blood mononuclear cells or T cells from which cells and T cells have been depleted. Examples of cellular reprogramming factors include genes or gene products such as Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, klf4, klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15-2, Tcl1, β-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3, and Glis1. These cellular reprogramming factors may be used alone or in combination. Among these cellular reprogramming factors, Oct3 / 4, Sox2, Klf4, and c-Myc (the so-called Yamanaka four factors) may be introduced into the peripheral blood mononuclear cells or T cells from the viewpoint of efficient establishment of iPS cells.
[0024] The method for introducing a cellular reprogramming factor into peripheral blood mononuclear cells or T cells is not particularly limited, and methods known in the art can be used.For example, when introducing a gene encoding the cellular reprogramming factor into peripheral blood mononuclear cells or T cells, the gene encoding the cellular reprogramming factor (e.g., cDNA) can be inserted into an expression vector containing a promoter that functions in the peripheral blood mononuclear cells or T cells, and the expression vector can be introduced into the peripheral blood mononuclear cells or T cells by infection, lipofection, liposome method, calcium phosphate coprecipitation, DEAE-dextran method, microinjection method, or electroporation method.When the cellular reprogramming factor is in the form of a protein and the protein is introduced into the peripheral blood mononuclear cells or T cells, examples of such methods include a method using a protein introduction reagent, a method using a protein introduction domain fusion protein, electroporation, and microinjection. When the cellular reprogramming factor is in the form of messenger RNA (mRNA) and the mRNA is introduced into the peripheral blood mononuclear cells or T cells, examples of the method include a method using an mRNA introduction reagent and a method of adding the mRNA to the culture medium.
[0025] Examples of expression vectors used for gene transfer by infection include viral vectors such as lentivirus, retrovirus, adenovirus, adeno-associated virus, herpes virus, and Sendai virus, as well as animal cell expression plasmids. However, from the viewpoints that insertional mutagenesis is unlikely to occur, gene transfer efficiency is high, and the number of copies of the transferred gene is large, Sendai virus may be used to transfer the gene encoding the cellular reprogramming factor into the peripheral blood mononuclear cells or T cells.
[0026] Examples of promoters used in expression vectors used when introducing a gene encoding the cellular reprogramming factor into peripheral blood mononuclear cells or T cells include the SRα promoter, SV40 promoter, LTR promoter, CMV promoter, RSV promoter, HSV-TK promoter, and ubiquitin promoter. These promoters may be capable of controlling the expression of a gene inserted downstream of the promoter depending on the presence or absence of a drug such as tetracycline. The expression vector may contain, in addition to the promoter, an enhancer, a poly(A) addition signal, a selection marker gene (e.g., a neomycin resistance gene), an SV40 origin of replication, and the like.
[0027] When T cells are used to generate iPS cells, the T cells may be stimulated with anti-CD3 and anti-CD28 antibodies in the presence of interleukin-2 (IL-2) or stimulated with a desired antigen peptide to activate them before cell reprogramming. The stimulation can be performed by adding IL-2, anti-CD3, and anti-CD28 antibodies to a culture medium and culturing the T cells for a certain period of time. The anti-CD3 and anti-CD28 antibodies may be coated on cell culture beads or cell culture plates that are dispersed in the culture medium. Furthermore, stimulation with an antigen peptide can be performed by adding a peptide consisting of a sequence of at least 9 amino acid residues that constitutes a desired antigen peptide recognized by T cells to the culture medium and culturing the T cells for a certain period of time.
[0028] The culture medium used for culturing iPS cells is not particularly limited, but can be prepared by adding cytokines to a culture medium used for culturing animal cells as a basal culture medium to maintain the undifferentiated potential of iPS cells. Examples of basal culture medium include IMDM (Iscove's Modified Dulbecco's Medium), Medium 199, EMEM (Eagle's Minimum Essential Medium), αMEM (alpha Modified Eagle Minimum Essential Medium), DMEM (Dulbecco's modified Eagle's Medium), Ham's F12 medium, RPMI1640 medium, Fischer's medium, Neurobasal Medium (Life Technologies), StemFit® AK03N (Ajinomoto Healthy Supply Co., Inc.), and mixtures thereof. The culture medium may contain serum or may be serum-free. An example of a cytokine is bFGF, and its concentration in the culture medium is, for example, 1 to 100 μg / mL.
[0029] iPS cells may be cultured by either adherent culture or suspension culture. When performing suspension culture, iPS cells can be cultured in a cell culture dish until they reach 80% confluence, dissociated into single cells, and then subjected to suspension culture. Examples of methods for isolating iPS cells include physical isolation using a cell scraper, or isolation using a dissociation solution with protease activity, collagenase activity, or both protease and collagenase activity (e.g., Accutase® and Accumax®).
[0030] [Induction of Differentiation from Pluripotent Stem Cells to Hematopoietic Stem Cells] In the present invention, "hematopoietic stem cells" refer to cells that can differentiate into blood cells such as lymphocytes, eosinophils, neutrophils, basophils, erythrocytes, and megakaryocytes. Hematopoietic stem cells and hematopoietic progenitor cells (HPCs) are not distinguished from each other and refer to the same cell type unless otherwise specified. Hematopoietic stem cells / progenitor cells are recognized, for example, by being positive for the surface antigen CD34 or by being double positive for CD34 and CD43.
[0031] Differentiation of pluripotent stem cells (iPS cells) into hematopoietic stem cells can be induced by culturing iPS cells in a culture medium supplemented with vitamin C. Vitamin C refers to L-ascorbic acid and its derivatives. L-ascorbic acid derivatives refer to compounds that are converted to vitamin C via enzymatic reactions in vivo. Examples of L-ascorbic acid derivatives include vitamin C phosphate, ascorbic acid glucoside, ascorbyl ethyl, vitamin C ester, ascorbyl tetrahexyldecanoate, ascorbyl stearate, and ascorbyl-2-phosphate-6-palmitate. Examples of vitamin C phosphate include L-ascorbate phosphates such as sodium L-ascorbate phosphate or magnesium L-ascorbate phosphate. Vitamin C is contained in the culture medium at a concentration of 5 to 500 μg / mL, for example.
[0032] The culture medium used to induce differentiation of iPS cells into hematopoietic stem cells is not particularly limited, but can be prepared by adding vitamin C or similar to a culture medium used for culturing animal cells as a basal culture medium. Examples of basal culture medium include IMDM (Iscove's Modified Dulbecco's Medium), Medium 199, EMEM (Eagle's Minimum Essential Medium), αMEM (alpha Modified Eagle Minimum Essential Medium), DMEM (Dulbecco's modified Eagle's Medium), Ham's F12 culture medium, RPMI1640 culture medium, Fischer's medium, Neurobasal Medium (Life Technologies), StemPro34 (Life Technologies), and mixtures thereof. The culture medium may contain serum or may be serum-free. The basal culture medium may contain, as needed, one or more substances selected from, for example, albumin, insulin, transferrin, selenium, fatty acids, trace elements, 2-mercaptoethanol, thiolglycerol, monothiolglycerol, lipids, amino acids, L-glutamine, non-essential amino acids, vitamins, growth factors, low-molecular-weight compounds, antibiotics, antioxidants, pyruvic acid, buffers, inorganic salts, and cytokines.
[0033] The culture medium used to induce differentiation of iPS cells into hematopoietic stem cells may further contain cytokines selected from the group consisting of bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), stem cell factor (SCF), thrombopoietin (TPO), and FMS-like tyrosine kinase ligand (FLT3L). The concentrations of these cytokines are, for example, 1 to 100 ng / mL for BMP4, VEGF, bFGF, TPO, and FLT3L, and 10 to 100 ng / mL for SCF.
[0034] To induce differentiation of pluripotent stem cells into hematopoietic stem cells, the cells may be co-cultured with feeder cells such as C3H10T1 / 2 (Takayama N, et al. J Exp Med. 2010; 2817-2830) or heterologous stromal cells (Niwa A, et al. J Ce11 Physiol. 2009; 221:367-77).
[0035] Hematopoietic stem cells can be prepared from embryoid bodies formed by culturing iPS cells. Here, embryoid bodies are three-dimensional sac-like structures with internal spaces derived from iPS cells, formed from endothelial cell populations and the like, and contain hematopoietic stem cells.
[0036] [T Cell Differentiation Inducing Factor] In the present invention, a Notch ligand for a Notch molecule expressed on the cell membrane can be used as a T cell differentiation inducing factor. Mammals have Notch molecules, Notch 1 to 4, and binding between a Notch molecule and a Notch ligand induces Notch signaling, which is involved in the control of cell survival, proliferation, and differentiation (Artavanis-Tsakonas S, et al. Science. 1999; 284:770-776). The Notch ligand is not particularly limited as long as it induces Notch signaling, and examples include Delta-Like-Protein (DLL) 1, 3, and 4, and Jagged 1 and 2. DLL1, DLL4, and Jagged 1 may also be used in the present invention. DLL4, an endogenous Notch1 ligand in mammals, particularly humans, may also be used in the present invention. The DLL4 may be a partial peptide of DLL4, as long as it induces Notch signaling. For example, a recombinant protein (DLL4-Fc) in which the Fc domain of human IgG1 is added to the C-terminus of the extracellular domain of human DLL4 (residue numbers 1 to 524 or residue numbers 27 to 529 (including mutations)) can be used.
[0037] [Wnt / β-catenin pathway activators] Signal transduction in the Wnt / β-catenin pathway is involved in numerous cellular processes and plays an important role in both animal development and regeneration (Gao J, et al. Cell Regeneration. 2021; 10:11). Wnt proteins primarily bind to the Frizzled receptor, a seven-transmembrane receptor protein, to initiate signal transduction. Binding of Wnt proteins to the receptor induces the accumulation of β-catenin, which then functions as an intracellular mediator of Wnt signaling. Wnt / β-catenin pathway activators enhance signal transduction in this pathway. Wnt / β-catenin pathway activators are not particularly limited as long as they enhance signal transduction, but examples include inhibitors of glycogen synthase kinase 3 (GSK-3), a serine / threonine kinase. After being phosphorylated by GSK-3 and the like, β-catenin is ubiquitinated and degraded by the proteasome, and GSK-3 inhibitors inhibit the degradation of β-catenin.
[0038] GSK-3 has two isoforms, GSK-3α and GSK-3β. In the present invention, any of a GSK-3α inhibitor, a GSK-3β inhibitor, and a GSK-3α / β dual inhibitor may be used as long as it enhances signal transduction in the Wnt / β-catenin pathway. CHIR-99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile) may also be used as a GSK-3 inhibitor. CHIR-99021 is also known as laduviglusib and is a compound with CAS number 252917-06-9. The concentration of the GSK-3 inhibitor added to the culture medium may be 0.01 to 100 μM.
[0039] [Cell adhesion factor] In the present invention, fibronectin or a fragment thereof can be used as the cell adhesion factor. Any region of fibronectin can be selected as the fibronectin fragment as long as it retains the function required in the present invention. Fibronectin may be derived from human or may be a recombinant protein. In the present invention, Retronectin (registered trademark, Takara Bio Inc.) can be used as the cell adhesion factor. Retronectin is an α-mer of human fibronectin. 5 β 1 It contains a cell adhesion domain (C-domain), a heparin-binding domain (H-domain), and α 4 β 1 It is a recombinant protein containing a CS-1 site that binds to integrin (VLA-4).
[0040] During cell culture, the T cell differentiation factor and the cell adhesion factor may be present in a coated state on a cell culture substrate. The term "coated" refers to the T cell differentiation factor and the cell adhesion factor being immobilized (coated) by adsorption or binding to the surface of the cell culture substrate. The coating can be achieved by diluting the T cell differentiation factor and the cell adhesion factor to 1 to 100 μg / mL, for example, with phosphate buffer, Hank's balanced salt solution, or a serum-, Ca-, and Mg-free culture medium, and contacting the diluted solution with the cell culture substrate for a certain period of time. Commercially available cell culture beads (microcarriers) or cell culture plates can be used as the cell culture substrate.
[0041] [Cell Culture] The cell culture in steps (1) to (3) of the first and second methods of the present invention may be either adherent culture or suspension culture. For adherent culture, a cell culture plate can be used as the cell culture substrate on which the T cell differentiation inducer and the cell adhesion factor are coated, while for suspension culture, cell culture beads can be used. In the first method, step (1) is performed in the presence of the T cell differentiation inducer, step (2) is performed in the presence of the T cell differentiation inducer and the cell adhesion factor, and step (3) is performed in the presence of the cell adhesion factor but in the absence of the T cell differentiation inducer. In the second method, step (1) is performed in the presence of the T cell differentiation inducer and the Wnt / β-catenin pathway activator, step (2) is performed in the presence of the cell adhesion factor, the Wnt pathway activator, and an anti-CD3 antibody, and step (3) is performed in the presence of the cell adhesion factor and the Wnt pathway activator but in the absence of the T cell differentiation inducer and the anti-CD3 antibody. The anti-CD3 antibody used in step (2) of the second method may be, for example, clone number OKT3. The concentration of the anti-CD3 antibody added to the culture medium may be 0.01 to 100 μg / mL.
[0042] Examples of basal culture media used for cell culture in steps (1) to (3) of the first and second methods of the present invention include IMDM (Iscove's Modified Dulbecco's Medium), Medium 199, EMEM (Eagle's Minimum Essential Medium), αMEM (alpha Modified Eagle Minimum Essential Medium), DMEM (Dulbecco's modified Eagle's Medium), Ham's F12 medium, RPMI1640 medium, Fischer's medium, Neurobasal Medium (Life Technologies), and mixtures thereof. Serum may be added to the culture medium or it may be serum-free. Serum may be added, for example, in an amount of 5 to 20% (v / v) fetal bovine serum. If necessary, the basal culture medium may contain one or more substances selected from the group consisting of albumin, insulin, transferrin, selenium, fatty acids, trace elements, 2-mercaptoethanol, thiolglycerol, monothiolglycerol, lipids, amino acids, L-glutamine, non-essential amino acids, vitamins, growth factors, low molecular weight compounds, antibiotics, antioxidants, pyruvic acid, buffers, inorganic salts, and cytokines.
[0043] In one embodiment of the first method of the present invention, the cell culture in steps (1) and (2) is carried out in the presence of interleukin-7 (IL-7) and FLT3L (FMS-like tyrosine kinase ligand). The concentrations of IL-7 and FLT3L in the culture medium are 0.1 to 50 ng / mL, and may also be 1 to 10 ng / mL.
[0044] In one embodiment of the first method of the present invention, the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, and SDF-1α (stromal cell-derived factor 1). The concentrations of IL-7, Flt3L, and 2-phospho-L-ascorbic acid in the culture medium are 0.1 to 200 μg / mL, and may also be 1 to 100 μg / mL. The concentration of SDF-1α in the culture medium is 0.1 to 100 nM, and may also be 1 to 20 nM.
[0045] In one embodiment of the first method of the present invention, the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, and a p38 inhibitor. The concentrations of IL-7, Flt3L, and 2-phospho-L-ascorbic acid in the culture medium are 0.1 to 200 μg / mL, and may further be 1 to 100 μg / mL. The concentration of the p38 inhibitor in the culture medium is 0.1 to 100 μM, and may further be 1 to 10 μM.
[0046] In one embodiment of the first method of the present invention, the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, a p38 inhibitor, and SDF-1α. The concentrations of IL-7 and Flt3L in the culture medium are 0.1 to 50 ng / mL, and may further be 1 to 10 ng / mL. The concentration of the p38 inhibitor in the culture medium is 0.1 to 100 μM, and may further be 1 to 10 μM. The concentration of SDF-1α in the culture medium is 0.1 to 100 nM, and may further be 1 to 20 nM.
[0047] In one embodiment of the first method of the present invention, the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, SDF-1α, and a p38 inhibitor. The concentrations of IL-7, Flt3L, and 2-phospho-L-ascorbic acid in the culture medium are 0.1 to 200 μg / mL, and may further be 1 to 100 μg / mL. The concentration of SDF-1α in the culture medium is 0.1 to 100 nM, and may further be 1 to 20 nM. The concentration of the p38 inhibitor in the culture medium is 0.1 to 100 μM, and may further be 1 to 10 μM.
[0048] In one embodiment of the first method of the present invention, the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, SDF-1α, a p38 inhibitor, and stem cell factor (SCF). The concentrations of IL-7, Flt3L, and 2-phospho-L-ascorbic acid in the culture medium are 0.1 to 200 μg / mL, and may be 1 to 100 μg / mL. The concentration of SDF-1α in the culture medium is 0.1 to 100 nM, and may be 1 to 20 nM. The concentration of the p38 inhibitor in the culture medium is 0.1 to 100 μM, and may be 1 to 10 μM. The concentration of SCF in the culture medium is 0.1 to 100 ng / mL, and may be 1 to 20 ng / mL.
[0049] In one embodiment of the first method of the present invention, the cell culture in step (3) is carried out in the presence of interleukin-7 (IL-7). The concentration of IL-7 in the culture medium is 0.1 to 50 ng / mL, and may also be 1 to 10 ng / mL.
[0050] In one embodiment of the first method of the present invention, the cell culture in step (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, and SDF-1α (stromal cell-derived factor 1). The concentrations of IL-7 and 2-phospho-L-ascorbic acid in the culture medium are 0.1 to 200 μg / mL, and may also be 1 to 100 μg / mL. The concentration of SDF-1α in the culture medium is 0.1 to 100 nM, and may also be 1 to 20 nM.
[0051] In one embodiment of the first method of the present invention, the cell culture in step (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, and a p38 inhibitor. The concentrations of IL-7 and 2-phospho-L-ascorbic acid in the culture medium are 0.1 to 200 μg / mL, and may further be 1 to 100 μg / mL. The concentration of the p38 inhibitor in the culture medium is 0.1 to 100 μM, and further may be 1 to 10 μM.
[0052] In one embodiment of the first method of the present invention, the cell culture in step (3) is carried out in the presence of IL-7, a p38 inhibitor, and SDF-1α. The concentration of IL-7 in the culture medium is 0.1 to 50 ng / mL, and may further be 1 to 10 ng / mL. The concentration of the p38 inhibitor in the culture medium is 0.1 to 100 μM, and may further be 1 to 10 μM. The concentration of SDF-1α in the culture medium is 0.1 to 100 nM, and may further be 1 to 20 nM.
[0053] In one embodiment of the first method of the present invention, the cell culture in step (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, SDF-1α, and a p38 inhibitor. The concentrations of IL-7 and 2-phospho-L-ascorbic acid in the culture medium are 0.1 to 200 μg / mL, and may further be 1 to 100 μg / mL. The concentration of SDF-1α in the culture medium is 0.1 to 100 nM, and may further be 1 to 20 nM. The concentration of the p38 inhibitor in the culture medium is 0.1 to 100 μM, and may further be 1 to 10 μM.
[0054] In one embodiment of the first method of the present invention, the cell culture in step (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, SDF-1α, a p38 inhibitor, and SCF (stem cell factor). The concentrations of IL-7 and 2-phospho-L-ascorbic acid in the culture medium are 0.1 to 200 μg / mL, and may further be 1 to 100 μg / mL. The concentration of SDF-1α in the culture medium is 0.1 to 100 nM, and may further be 1 to 20 nM. The concentration of the p38 inhibitor in the culture medium is 0.1 to 100 μM, and may further be 1 to 10 μM. The concentration of SCF in the culture medium is 0.1 to 100 ng / mL, and may further be 1 to 20 ng / mL.
[0055] In one embodiment of the second method of the present invention, the cell culture in step (1) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, SDF-1α, a p38 inhibitor, SCF, and TPO (thrombopoietin). The concentrations of IL-7, FLT3L, SCF, and TPO in the culture medium are 1 to 500 ng / mL, and may be 10 to 100 ng / mL. The concentration of 2-phospho-L-ascorbic acid in the culture medium is 1 to 1000 μg / mL, and may even be 5 to 100 μg / mL. The concentration of SDF-1α in the culture medium is 0.1 to 500 nM, and may even be 1 to 100 nM. The concentration of the p38 inhibitor in the culture medium is 0.1 to 200 μM, and may even be 1 to 50 μM.
[0056] In one embodiment of the second method of the present invention, the cell culture in steps (2) and (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, SDF-1α, and a p38 inhibitor. The concentration of IL-7 in the culture medium is 1 to 500 ng / mL, and may be 10 to 100 ng / mL. The concentration of 2-phospho-L-ascorbic acid in the culture medium is 1 to 1000 μg / mL, and may even be 5 to 100 μg / mL. The concentration of SDF-1α in the culture medium is 0.01 to 200 nM, and may even be 1 to 50 nM. The concentration of the p38 inhibitor in the culture medium is 0.1 to 100 mM, and may even be 1 to 50 mM.
[0057] In the culture medium used in steps (1) to (3) of the first and second methods of the present invention, isoforms such as SDF-1β, SDF-1γ, SDF-1δ, SDF-1ε, or SDF-1φ may be used in place of SDF-1α, or a mixture of these isoforms in any ratio may be used.
[0058] The p38 inhibitor is defined as a substance that inhibits the function of p38 protein (p38 MAP kinase). Examples of p38 inhibitors include chemical inhibitors of p38. Examples of chemical inhibitors of p38 include SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole) and its derivatives, SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole) and its derivatives, and SB239063. Examples include, but are not limited to, (trans-4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol) and its derivatives, SB220025 and its derivatives, PD169316, RPR200765A, AMG-548, BIRB-796, SCI0-469, SCI0-323, VX-702 and FR167653.
[0059] The cell culture temperature in steps (1) to (3) of the first and second methods of the present invention is not particularly limited as long as it does not inhibit cell growth and survival, but the cell culture can be performed at about 37°C to about 42°C, and may also be performed at about 37°C to about 39°C.
[0060] The culture period in step (1) of the first and second methods of the present invention can be determined by confirming the formation of T cell precursors. In the present invention, the term "T cell precursors" refers to CD3-, CD5-, and CD1a-positive cells that are fully committed to the T cell lineage. The T cell precursors include not only CD4 / CD8-double-positive immature T cells but also CD4-single-positive immature T cells. These cell surface antigens can be detected by flow cytometry using fluorescently labeled antibodies against the cell surface antigens. In one embodiment of the present invention, the cells obtained in step (1) may proceed to the next step (2) after confirming the appearance of CD3-, CD1a-, and CD5-positive T cell precursors. That is, the step of confirming that the cells obtained in step (1) contain CD3-, CD1a-, and CD5-positive T cell precursors may be a step of determining whether to proceed from step (1) to step (2). The culture period in step (1) is not particularly limited as long as CD3- and CD5-positive cells are obtained, but may be, for example, 10 to 30 days.
[0061] The culture period in step (2) of the first method of the present invention can be determined by confirming the formation of CD3-positive and CD4 / CD8 double-positive immature T cells. In one embodiment of the present invention, after confirming the presence of CD3-positive and CD4 / CD8 double-positive immature T cells in the culture of step (2), the method may proceed to the next step (3). That is, the step of confirming that the cells obtained in step (2) contain CD3-positive and CD4 / CD8 double-positive immature T cells can be a step of determining whether to proceed from step (2) to step (3). In one embodiment of the present invention, after confirming that the cells obtained in step (2) contain CD3-positive and CD4 / CD8 double-positive immature T cells and further contain CD5- and CD1a-positive cells, the method may proceed to the next step (3). That is, the step of confirming that the cells obtained in step (2) contain CD3-positive and CD4 / CD8 double-positive immature T cells and further contain CD5- and CD1a-positive cells can be a step of determining whether to proceed from step (2) to step (3). The culture period in step (2) is not particularly limited as long as CD3-positive and CD4 / CD8 double-positive cells can be obtained, but may be, for example, 3 to 10 days.
[0062] The culture period in step (3) of the first and second methods of the present invention can be determined by confirming the formation of mature helper T cells that are CD1a and CD8 negative, and CD5 positive and CD4 single positive, or a mixture of the mature helper T cells and mature killer T cells that are CD5 and CD8 positive and CD1a and CD4 negative. Confirming the formation of mature helper T cells that are CD1a and CD8 negative, and CD5 positive and CD4 single positive, or a mixture of the mature helper T cells and mature killer T cells that are CD5 and CD8 positive and CD1a and CD4 negative, among the cells obtained in step (3), indicates that a cell population containing CD4 single positive and CD8 negative helper T cells has been obtained. In the methods of the present invention, mature helper T cells and mature killer T cells may be formed simultaneously. The culture period in step (3) is not particularly limited as long as mature helper T cells that are CD1a and CD8 negative, CD5 positive and CD4 single positive are obtained, but may be, for example, 2 to 20 days.
[0063] In one embodiment of the first and second methods of the present invention, the cells obtained in step (3) may be confirmed to contain T cells highly expressing CD28. The term "high expression" means that the CD28 expression level is equivalent to that of primary T cells obtained from peripheral blood. CD28 is a costimulatory receptor essential for T cell activation, and therefore serves as an indicator that the obtained cells are functional helper T cells. That is, the step of confirming that the cells obtained in step (3) contain T cells highly expressing CD28 may be a step of determining whether the helper T cells obtained by the method of the present invention are functional helper T cells. In one embodiment of the present invention, the cells obtained in step (3) may be confirmed to exhibit a CD28 expression level equivalent to that of mature T cells present in human peripheral blood. The term "equivalent" means that the CD28 expression level is comparable to that of a naive T cell fraction expressing CD28 most highly, to the extent that it is difficult to distinguish the CD28 expression level in flow cytometry analysis.
[0064] In one embodiment of the first method of the present invention, the cell culture in steps (1) and (2) is carried out while maintaining the cell density at subconfluence. Confluence refers to a state in which the cell adhesion surface of the cell culture substrate is completely covered with cultured cells, leaving no room for the cells to grow as a monolayer. In the present invention, "subconfluence" refers to a state in which 50 to 90% of the adhesion surface of the culture vessel is occupied by cultured cells, and the occupancy rate of the adhesion surface of the culture vessel by the cultured cells may be 60 to 80%.
[0065] The first and second methods of the present invention, which include steps (1) to (3), can produce a cell population containing CD4 single-positive and CD8-negative helper T cells. The term "cell population" refers to cells that may be classified as CD4 single-positive / CD8-negative helper T cells, but may also include a variety of cells, such as cells with different cell surface antigen expression patterns and CD4 negative / CD8 positive killer T cells. The resulting CD4 positive / CD8 negative helper T cells and CD4 negative / CD8 positive killer T cells may be used individually or as a mixture. Isolation can be performed using methods well known in the art. For example, methods include labeling with antibodies against CD4, CD8, CD3, and / or CD45 and isolating using a flow cytometer, or purifying using an affinity column on which the desired antigen is immobilized.
[0066] [Introduction of a cell surface molecule reactive to a tumor-associated antigen into a cell] A nucleic acid encoding a chimeric antigen receptor (CAR) or T cell receptor (TCR) molecule reactive to a tumor-associated antigen can be introduced from outside the cell into the pluripotent stem cells or iPS cells, the T precursor cells, the hematopoietic stem cells, the immature T cells, or the mature T cells.
[0067] When introducing a TCR, cDNA encoding the TCR α and β chains or cDNA encoding the γ and δ chains can be prepared and incorporated into an expression vector. These cDNAs can be incorporated into a viral or non-viral vector (transposon vector), for example, using the Gibson assembly system. Specifically, downstream of a ubiquitin promoter, a gene in which cDNA encoding the TCR α and TCR β chains is linked via a T2A sequence is ligated, and further downstream, a marker gene such as EGFR with the ligand binding site and intracellular domain removed (EGFRt, truncated EGFR) or CD19 lacking the intracellular domain is linked to an IRES (internal ribosome entry site) sequence, and this construct can be incorporated into a viral or non-viral vector. The cDNA encoding the TCR α chain and the cDNA encoding the β chain can also be incorporated into separate expression vectors.
[0068] When introducing a CAR, cDNA encoding the CAR can be prepared and incorporated into an expression vector. For example, total RNA is extracted from the lymph nodes of an animal immunized with a desired tumor-associated antigen and used as a template to synthesize cDNA; the light and heavy chains of the variable regions of a monoclonal antibody against the tumor-associated antigen are separately amplified, linked using a flexible linker, and amplified by assembly PCR; a CAR construct can be prepared by linking the sequences encoding the fused light and heavy chains to a sequence encoding the intracellular domain of the CAR molecule via a sequence encoding the transmembrane domain of the CAR molecule. To confirm the expression of the introduced gene, EGFR (EGFRt) lacking the ligand-binding site and intracellular domain may be linked to the CAR construct via a T2A sequence. The flexible linker that connects the light chain and heavy chain of the variable region of a monoclonal antibody is a linker peptide of about 5 to 20 amino acid residues, and is known in the art (see, for example, Ueda T, et al. Cancer Sci. 2020; 111:1478-1490. Kawasaki Tomomi et al., SCEJ 72nd Annual Meeting (Kyoto, 2007) H209.).
[0069] The antigen-binding domain to be incorporated into the CAR may be prepared by phage display without immunizing an animal with the antigen. For example, an antibody that specifically binds to a desired tumor-associated antigen may be screened from a phage display antibody library expressing the Fab regions of a large number of human antibodies.
[0070] A TCR or CAR reactive to a tumor-associated antigen may be introduced into the cells alone, or a TCR and a CAR may be introduced simultaneously. When a TCR and a CAR are introduced simultaneously, the expression vectors may be the same or different. When a TCR and a CAR are introduced simultaneously, the TCR and the CAR may be reactive to the same tumor-associated antigen or may be reactive to different tumor-associated antigens.
[0071] Viral and non-viral vectors can be used as expression vectors. Examples of viral vectors include lentivirus, retrovirus, adenovirus, adeno-associated virus, herpesvirus, and Sendai virus, as well as animal cell expression plasmids. Lentivirus or retrovirus can be used preferably. When retrovirus or lentivirus infection is performed, spin infection or the like may be used. Examples of non-viral vectors include the piggyBac (registered trademark) vector, which is a transposon vector. Genome editing techniques may be used to replace the endogenous TCR of iPS cells with a TCR or CAR introduced from outside the cells. Examples of such genome editing techniques include the CRISPR / Cas9 method, the CRISPR / MAD method, and the CRISPR / CAS3 method. Methods for gene transfer using non-viral vectors or methods for introducing guide RNA and donor DNA for genome editing include the lipofection method, liposome method, calcium phosphate coprecipitation method, DEAE-dextran method, microinjection method, and electroporation method. Gene transfer of TCR and / or CAR may be performed at the TCR locus or other loci (e.g., the β2-microglobulin locus). When modification or disruption of existing genes, including TCR, by the transgene is not desired, the gene may be transferred to a safe harbor locus. Examples of such safe regions include the AAVS1 (Adeno-associated virus integration site 1) region in the human genome. Examples of methods for gene transfer targeting such safe regions include the CRISPR / Cas9 method and the TALEN method.
[0072] "Tumor-associated antigens" are antigens that are expressed specifically or nonspecifically in tumors, including antigens derived from proteins overexpressed in tumor cells and their mutants, antigens derived from tumor viruses, certain differentiation antigens, and novel tumor-associated antigens (neoantigens) resulting from gene mutations and splice aberrations. In the case of protein antigens, they may be fragmented peptides (peptide fragments). Antigens expressed specifically or non-specifically in tumors include WT1, GPC3, BCMA, XAGE1, MUC1, MUC5A1, MUC6, EGFRvIII, HER-2 / neu, MAGE-A1, MAGE-A3, telomerase, PRAME, SSX2 / 4, PSCA, CTLA-4, gp100, GD2, GD3, fucosyl GM1, GM3, sLe(a), glycolipid F77, mesothelin, PD-L1, trp1, trp2, CD19, CD20, CD22, ROR1, CD33, c-Met, and genes Examples of neoantigens include, but are not limited to, p53 without mutation, p53 with genetic mutation, p53 mutant, NY-ESO-1, PSMA, ETV6-AML, CEA, PSA, AFP, hTERT, EpCAM, ALK, androgen receptor, EphA2, CYP1B1, OY-TES-1, MAD-CT-2, MelanA / MART1, survivin, Ras, Ras mutant, EGR, bcr-abl, XBP-1, neoantigens due to genetic mutations, and neoantigens due to splice aberrations. Viral antigens include, but are not limited to, HBV, HBs, HPV, EBV, LMP1, EBV, LMP2, EBNA, HPV-E1, HPV-E2, HPV-E6, HPV-E7, HTLV-1 Tax, and HBZ.
[0073] [Medicine containing a cell population produced by the method of the present invention] A pharmaceutical containing a cell population produced by the method of the present invention can be used as a preventive or therapeutic agent for cancer in mammals. The pharmaceutical of the present invention may be produced by a method conventionally used in the pharmaceutical technology field. The pharmaceutical of the present invention may contain a pharmaceutically acceptable additive. Examples of the additive include a cell culture medium, physiological saline, and an appropriate buffer solution (e.g., a phosphate buffer solution).
[0074] The pharmaceutical of the present invention can be produced by suspending the cells of the present invention in physiological saline or an appropriate buffer solution (e.g., phosphate buffer solution). The amount of the cells to be administered per dose is, for example, 1 x 10 7 pcs or more, 1×10 8 or more or 1 x 10 9 The pharmaceutical composition of the present invention may contain one or more cells. The cell content can be adjusted taking into consideration the gender, age, weight, condition of the affected area, and cell condition of the recipient. In addition to the cells of the present invention, the pharmaceutical composition of the present invention may contain dimethyl sulfoxide (DMSO) and serum albumin for the purpose of protecting the cells. It may also contain antibiotics to prevent bacterial contamination. It may also contain vitamins and cytokines for the purpose of promoting cell activation and differentiation. Furthermore, the pharmaceutical composition of the present invention may contain other pharmaceutically acceptable components (e.g., carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, antiseptics, physiological saline, etc.).
[0075] Pharmaceuticals containing the cells of the present invention can be cryopreserved. When cryopreserved, the storage temperature is not particularly limited as long as it is a temperature suitable for storing cells. Examples include -20°C, -80°C, and -120 to -196°C, with -150°C or lower being preferred. When cryopreserved, the cells may be stored in an appropriate container such as a cryovial or a cryobag.
[0076] The medicament of the present invention is used for the prevention or treatment of cancer, including, but not limited to, ovarian cancer, hepatoblastoma, hepatocellular carcinoma, gastric cancer, esophageal cancer, pancreatic cancer, renal cell carcinoma, breast cancer, malignant melanoma, non-small cell lung cancer, cervical cancer, glioblastoma, prostate cancer, neuroblastoma, chronic lymphocytic leukemia, papillary thyroid cancer, colorectal cancer, head and neck cancer, brain tumor, multiple myeloma, and B-cell non-Hodgkin's lymphoma.
[0077] The cells of the present invention can kill cells that express tumor-associated antigens, and can therefore be used as an agent for killing cells that express tumor-associated antigens. The agent can be produced and used in the same manner as the pharmaceutical.
[0078] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.
[0079] [Preparation of CD4 single-positive helper T cells from iPS cells (Method 1)] iPS cells were prepared from CD3-positive T cells isolated from human peripheral blood using the method described in Non-Patent Document 3. A pan T cell isolation kit (Pan T Cell Isolation Kit, Miltenyi Biotec, catalog number: 130-096-535) was used to isolate the T cells.
[0080] (Day 0) To each well of a 48-well cell culture plate (Corning, catalog number: 3548), 150 μL of a DLL4-Fc solution (Shino Bio, catalog number: 10171-H02H) diluted to 5 μg / mL with phosphate-buffered saline (PBS) was added and the plate was left standing at 4°C overnight to coat the plate with human DLL4-Fc. DLL4-Fc is a recombinant protein in which the Fc domain of human IgG1 is attached to the C-terminus of the extracellular domain (residues 1 to 524) of human DLL4 (Delta-Like Protein 4), and it was used as a T cell differentiation inducer.
[0081] Days 1 to 14: Step (1) (Day 1) Embryoid bodies formed by suspension culture of iPS cells for 11 days were collected and dispersed into single cells by repeated suction and ejection six times using a syringe equipped with a 21-gauge needle. Cell debris was then removed using a cell strainer. The obtained cells were suspended in T cell differentiation medium at a cell concentration of 4 x 10 4 The DLL4-Fc-coated cell culture plate was washed once with 1 mL / well of PBS, and then 500 μL / well of the T cell differentiation medium was added. 4The cells added to the cell culture plate were incubated at 37°C, 5% CO while replacing half of the culture medium with fresh T cell differentiation medium every 2 to 3 days. 2 During the culture, the cell density was maintained at 70-80% confluence or less.
[0082] The T cell differentiation culture medium contained 15% fetal bovine serum (Nacalai Tesque, 01863-48), PSG (penicillin-streptomycin-L-glutamine) solution (100x, Sigma-Aldrich, catalog number: G1146-100ML), ITS (insulin-transferrin-sodium selenite) supplement (100x, Invitrogen, catalog number: 41400045), 2-phospho-L-ascorbic acid (final concentration 50 μg / mL, Sigma-Aldrich, catalog number: A8960-5G), human recombinant IL-7 (final concentration 5 ng / mL, PeproTech, catalog number: 200-07), human recombinant Flt3L (final concentration 5 ng / mL, PeproTech, catalog number: 300-19), and human recombinant SCF (final concentration 10 ng / mL, R&D Systems, Catalog No.: 255-SC), human recombinant SDF-1α (final concentration 10 nM, PeproTech, Catalog No.: 300-28A), and the p38 inhibitor SB203580 (final concentration 10 μM, Tocris Bioscience, Catalog No.: 1202) were added to alpha Modified Eagle Minimum Essential Medium (αMEM, Gibco, Catalog No.: 12571-063).
[0083] (Day 7) A new 48-well cell culture plate was coated with DLL4-Fc in the same manner as on Day 0. (Day 8) The new 48-well cell culture plate coated with DLL4-Fc was washed once with 1 mL / well of PBS, and then 500 μL / well of the T cell differentiation medium was added. 1 to 2 × 10 cells were added to the plate. 5The cells added to the new cell culture plate were incubated at 37°C, 5% CO while replacing half of the culture medium with fresh T cell differentiation medium every 2 to 3 days. 2 During the culture, the cell density was maintained at about 70-80% confluence or less.
[0084] (Day 14) The obtained cells were analyzed by flow cytometry, and it was confirmed that the cells differentiated from the iPS cells contained precursor T cells that were positive for both CD3 and CD5.
[0085] To each well of a new 48-well cell culture plate, 150 μL of PBS containing 5 μg / mL of human DLL4-Fc and RetroNectin (RetroNectin, registered trademark, Takara Bio) was added and left to stand overnight at 4°C to coat the cell culture plate with human DLL4-Fc and RetroNectin. RetroNectin was used as a cell adhesion factor.
[0086] Days 15 to 21: Step (2) (Day 15) The cell culture plate coated with DLL4-Fc and retronectin was washed once with 1 mL / well of PBS, and then the T cell differentiation medium was added at 500 μL / well. A cell suspension (2 to 4 × 10 cells) containing the CD3- and CD5-positive T cell precursors was added thereto. 5 The cells were incubated at 37°C, 5% CO with half of the culture medium replaced with fresh T cell differentiation medium every 2 to 3 days. 2 During the culture, the cell density was maintained at about 70-80% confluence or less.
[0087] (Day 21) The obtained cells were analyzed by flow cytometry, and it was confirmed that the cells differentiated from the T precursor cells included T cells that were CD3 positive, CD4 / CD8 double positive, and CD5 and CD1a positive.
[0088] To each well of a new 48-well cell culture plate, 150 μL of a Retronectin solution diluted to 5 μg / mL with PBS was added, and the plate was left standing overnight at 4° C. to coat the cell culture plate with Retronectin.
[0089] Days 22 to 35: Step (3) (Day 22) A culture medium (Flt3L-free T cell differentiation culture medium) was prepared by removing human recombinant Flt3L from the T cell differentiation culture medium. The new cell culture plate coated with Retronectin was washed once with 1 mL / well of PBS, and then 500 μL / well of the Flt3L-free T cell differentiation culture medium was added. 8 × 10 T cells that had been cultured and differentiated in the cell culture plate up to this point were added. 5 The Flt3L-free T cell differentiation medium containing 100 cells / mL of Flt3L was added at 500 μL / well. Thereafter, the cells were incubated at 37°C, 5% CO while replacing half of the culture medium with fresh Flt3L-free T cell differentiation medium every 2 to 3 days. 2 It was cultivated under the environment.
[0090] (Day 28) A new 48-well cell culture plate was coated with RetroNectin in the same manner as on Day 21. (Day 29) The new 48-well cell culture plate coated with RetroNectin was washed once with 1 mL / well of PBS, and the Flt3L-free T cell differentiation medium was added at 500 μL / well. The culture medium in the wells containing the T cells cultured in the cell culture plate up to this point was reduced to 500 μL, and all of the cells contained in each well were transferred together with the culture medium to each well of the new 48-well cell culture plate, and the plate was further incubated at 37°C and 5% CO 2 It was cultivated under the environment.
[0091] (Day 35) Flow cytometry analysis of the obtained cells confirmed the presence of mature helper T cells that were CD4 single positive, CD8 negative, CD5 and CD3 positive, and CD1a negative.Furthermore, the presence of mature killer T cells that were CD8 single positive, CD4 negative, CD5 and CD3 positive, and CD1a negative was also confirmed.
[0092] [Effect of Coating Cell Culture Plates with DLL4-Fc and RetroNectin on the Generation of CD4 Single-Positive Helper T Cells from iPS Cells (1)] The effect of coating cell culture plates with DLL4-Fc and RetroNectin on the generation of CD4 single-positive helper T cells from iPS cells was examined in each of step (1) (days 1 to 14), step (2) (days 15 to 21), and step (3) (days 22 to 35) shown in Example 1. For this examination, cells were cultured using various combinations of coatings on the cell culture plates in each step. Coating with DLL4-Fc and RetroNectin, iPS cell culture, and culture conditions were similar to those in Example 1.
[0093] The combinations of DLL4-Fc and Retronectin coating of cell culture plates in each step are shown in Table 1. In Table 1, coating combination (c) is the coating condition used in Example 1. That is, in coating combination (c), cells were cultured using cell culture plates coated with DLL4-Fc only in step (1) (days 1 to 14), cell culture plates coated with DLL4-Fc and Retronectin in step (2) (days 15 to 21), and cell culture plates coated with Retronectin only in step (3) (days 22 to 35). The results of flow cytometric analysis of CD4 single-positive helper T cell generation in coating combinations (a) to (h) are shown in Figure 1. The values shown in each dot plot in Figure 1 indicate the percentages (%) of CD3 and CD5 positive / CD1a negative / CD4 single-positive mature helper T cells in the cell population obtained on day 35 of the culture schedule. These percentages are also shown in Table 1. (Table 1) (Abbreviations used in the table) D: DLL4-Fc R: Retronectin CD4SP iPSC-T cells: CD4 single positive helper T cells induced from iPS cells
[0094] Figure 1 and Table 1 demonstrate that the presence or absence of DLL4-Fc (a T cell differentiation inducer) and retronectin (a cell adhesion factor) in each step is important for generating CD4 single-positive helper T cells from iPS cells. Specifically, the combination of DLL4-Fc single-coating in step (1) (days 1 to 14), double-coating of DLL4-Fc and retronectin in step (2) (days 15 to 21), and retronectin single-coating in step (3) (days 22 to 35) (coating combination (c)) resulted in a significantly higher proportion of CD4 single-positive helper T cells in total cells compared with other combinations. On the other hand, as shown in Figure 1, the presence or absence of coating on the cell culture plate was not important for generating CD8 single-positive killer T cells from iPS cells.
[0095] [Effect of Coating Cell Culture Plates with DLL4-Fc and Retronectin on the Generation of CD4 Single-Positive Helper T Cells from iPS Cells (2)] The effect of coating cell culture plates with DLL4-Fc and Retronectin on the generation of CD4 single-positive helper T cells from iPS cells was examined in step (3) (days 22 to 35) shown in Example 1. Coating with DLL4-Fc and Retronectin, iPS cell culture, and culture conditions were similar to those in Example 1.
[0096] The combinations of DLL4-Fc and RetroNectin coating of the cell culture plates in step (3) are shown in Table 2. The coating conditions were the same for steps (1) and (2). In Table 2, "coating combination (c)" refers to the coating conditions used in Example 1. The results of flow cytometry analysis of CD4 single-positive helper T cells for coating combinations (i), (c), and (d) are shown in Figure 2. The results indicated that, in step (3), "coating combination (c)," in which the cell culture plates were coated with RetroNectin, produced a higher amount of CD4 single-positive helper T cells than "coating combination (i)," in which the cell culture plates were not coated, and "coating combination (d)," in which the cell culture plates were double-coated with DLL4-Fc and RetroNectin. Furthermore, the percentages (%) of CD3 and CD5 positive / CD1a negative / CD4 single-positive mature helper T cells in the cell populations obtained on day 35 of the culture schedule were compared among coating combinations (i), (c), and (d). The results (mean ± standard error) are shown in Table 2 and Figure 3. The n numbers in Table 2 indicate the number of independent tests. Statistical analysis was performed using a paired t-test. Coating combination (c) showed a statistically significantly higher percentage of CD3 and CD5 positive / CD1a negative / CD4 single positive mature helper T cells compared with (i) and (d) ( Figure 3 ). It was shown that coating with RetroNectin alone in step (3) was effective for generating CD4 single positive helper T cells (Table 2). (Abbreviations used in the table) D: DLL4-Fc R: Retronectin -: No coating CD4SP iPSC-T cells: CD4 single positive helper T cells induced from iPS cells
[0097] [Effect of Coating Cell Culture Plates with DLL4-Fc and Retronectin on the Generation of CD4 Single-Positive Helper T Cells from iPS Cells (3)] The results obtained in Example 3 showed that coating the culture plate with Retronectin alone in step (3) increased the amount of CD4 single-positive helper T cells generated. Therefore, the effect of combining coating the cell culture plate with DLL4-Fc and Retronectin in step (1) (days 1 to 14) and step (2) (days 15 to 21) on the generation of CD4 single-positive helper T cells from iPS cells was examined. Specifically, the effect of coating with Retronectin in addition to DLL4-Fc in steps (1) and (2) was examined. The coating with DLL4-Fc and Retronectin, the culture of iPS cells, and the culture conditions were similar to those in Example 1.
[0098] Table 3 shows the combinations of DLL4-Fc and RetroNectin coating of cell culture plates in steps (1) and (2). The coating conditions for step (3) were the same. In Table 3, "coating combination (c)" refers to the coating conditions used in Example 1. Figure 4 shows the results of flow cytometry analysis of CD4 single-positive helper T cells generated by coating combinations (a), (c), (e), and (g). The results showed that, with respect to steps (1) and (2), "coating combination (c)," in which the cell culture plate was additionally coated with RetroNectin only in step (2), produced a higher amount of CD4 single-positive helper T cells than "coating combination (a)," in which the cell culture plate was not coated with RetroNectin; "coating combination (e)," in which RetroNectin was additionally coated only in step (1); and "coating combination (g)," in which RetroNectin was additionally coated in steps (1) and (2). Furthermore, the percentages (%) of CD3 and CD5 positive / CD1a negative / CD4 single positive mature helper T cells in the cell populations obtained on day 35 of the culture schedule were compared among coating combinations (a), (c), (e), and (g). The results (mean ± standard error) are shown in Table 3 and Figure 5. The n values in Table 3 indicate the number of independent experiments. Statistical analysis was performed using a paired t-test. Coating combination (c) showed a statistically significantly higher percentage of CD3 and CD5 positive / CD1a negative / CD4 single positive mature helper T cells compared with coating combinations (a), (e), and (g) (Figure 5). It was shown that the combination of DLL4-Fc single coating in step (1) and the combination of DLL4-Fc and Retronectin double coating in step (2) were effective for generating CD4 single positive helper T cells (Table 3). (Abbreviations used in the table) D: DLL4-Fc R: Retronectin CD4SP iPSC-T cells: CD4 single positive helper T cells induced from iPS cells
[0099] [Effect of Wnt / β-catenin pathway activators on the generation of CD4 single-positive helper T cells from iPS cells] The effect of adding a Wnt / β-catenin pathway activator on the generation of CD4 single-positive helper T cells was examined in steps (1), (2), and (3) shown in Example 1. The test was performed in accordance with Example 1, except that iPS cells transfected with a specific TCR were used. The coating conditions for DLL4-Fc and retronectin were as follows: coating combination (c) (see Tables 1 to 3). The GSK-3 inhibitor CHIR-99021 was used as the Wnt / β-catenin pathway activator, and was added at a concentration of 1 μM in steps (1), (2), and (3).
[0100] The percentages (%) of CD3 and CD5 positive / CD1a negative / CD4 single positive mature helper T cells in the cell populations obtained on day 35 of the culture schedule were compared in the presence and absence of CHIR-99021. Four independent experiments were performed, and the results are shown in Figure 6. The percentage of CD4 single positive mature helper T cells was statistically significantly higher in the presence of CHIR-99021 than in the absence of CHIR-99021. Statistical analysis was performed using a paired t-test.
[0101] [CD40L Expression by TCR Stimulation of CD4 Single-Positive Helper T Cells (CD4SP iPSC-T Cells) Generated from iPS Cells (1)] CD40L (CD40 ligand) is an effector molecule expressed primarily on activated CD4-positive T cells and is involved in dendritic cell maturation. CD40L expression in cell populations containing CD4SP iPSC-T cells matured by DLL4-Fc / retronectin switching in the coating of cell culture plates according to Example 1 was analyzed by flow cytometry and compared with that of conventional CD4SP iPSC-T cells matured from iPS cells using an anti-CD3 antibody (OKT3) as previously reported (WO 2018 / 135646). Flow cytometry analysis of the CD4SP iPSC-T cells matured by DLL4-Fc / retroNectin switching was performed 4 days after TCR stimulation with anti-CD3 antibodies coated on cell culture plates in the presence of IL-7, IL-12, IL-15, IL-18, and IL-21. The analysis results are shown in Figure 7. In Figure 7, the upper panel shows the analysis results for conventional CD4SP iPSC-T cells matured with anti-CD3 antibodies, and the lower panel shows the analysis results for CD4SP iPSC-T cells matured by DLL4-Fc / retroNectin switching.
[0102] The results in Figure 7 indicate that CD4SP iPSC-T cells matured by DLL4-Fc / retronectin switching exhibited higher CD40L expression upon TCR stimulation than CD4SP iPSC-T cells matured with an anti-CD3 antibody. Specifically, CD4SP iPSC-T cells matured by DLL4-Fc / retronectin switching contained 24.3% highly CD40L-expressing cells, whereas CD4SP iPSC-T cells matured with an anti-CD3 antibody contained only 2.91% highly CD40L-expressing cells. These results suggest that CD4SP iPSC-T cells matured by DLL4-Fc / retronectin switching also function better as helper T cells than conventional CD4SP iPSC-T cells matured with an anti-CD3 antibody.
[0103] CD40L Expression by CD4 Single-Positive Helper T Cells (CD4SP iPSC-T Cells) Generated from iPSCs (2) Upon TCR Stimulation: CD4SP iPSC-T Cells and CD8 Single-Positive Killer T Cells (CD8SP iPSC-T Cells) were isolated from a cell population containing CD4SP iPSC-T cells and CD8 Single-Positive Killer T Cells (CD8SP iPSC-T Cells) that were matured without feeder cells by DLL4-Fc / retronectin switching in the coating of cell culture plates, as described in Example 1. Furthermore, CD4 Single-Positive Helper T Cells (ATO-CD4SP iPSC-T Cells) and CD8 Single-Positive Killer T Cells (ATO-CD8SP iPSC-T Cells) were isolated from T cells generated from iPSCs by culture in an artificial thymic organ (ATO; see Non-Patent Document 6) on feeder cells. Furthermore, CD4 single-positive helper T cells and CD8 single-positive killer T cells were isolated from primary T cells derived from peripheral blood of healthy donors. CD40L expression in these cells was analyzed by flow cytometry. Flow cytometry analysis was performed 24 hours after stimulation of each cell type with anti-CD3 antibody (1 μg / mL) immobilized on a cell culture plate in the presence of IL-7 (5 ng / mL), IL-12 (50 ng / mL), IL-15 (5 ng / mL), IL-18 (50 ng / mL), and IL-21 (20 ng / mL).
[0104] The CD40L expression of each cell type was measured as the mean fluorescence intensity by flow cytometry analysis and the results are shown in Figure 8. The results in Figure 8 are expressed as the mean ± standard error, and statistical analysis was performed using a paired t-test. CD4SP iPSC-T cells matured without feeder cells were shown to express significantly more CD40L than feeder-free CD8SP iPSC-T cells, ATO-CD8SP iPSC-T cells, and primary T cells (CD4 single-positive helper T cells and CD8 single-positive killer T cells) derived from healthy individuals. The CD40L expression level of feeder-free CD4SP iPSC-T cells was comparable to that of ATO-CD4SP iPSC-T cells. This suggests that CD4SP iPSC-T cells matured by the DLL4-Fc / retronectin switching pathway exhibit superior helper T cell function.
[0105] [Expression of Thpok and PLZF in CD4 Single Positive Helper T Cells (CD4SP iPSC-T Cells) and CD8 Single Positive Killer T Cells (CD8SP iPSC-T Cells) Generated from iPS Cells] Thpok is a master transcription factor for helper T cell differentiation and is essential for helper T cell function. PLZF is a master transcription factor for the differentiation of innate immune T cells such as natural killer T (NKT) cells. Mature CD4SP iPSC-T cells and CD8SP iPSC-T cells were obtained by culturing iPS cells with DLL4-Fc / retronectin switching on the coating of cell culture plates, as described in Example 1. The expression of these two transcription factors in these T cells was compared with that of adaptive immune primary T cells obtained from peripheral blood. The expression of these transcription factors was measured by TaqMan qPCR (quantitative PCR). For Thpok measurement, the reagent set used was Assay ID: Hs00757087_g1 (Gene: Zbtb7b) (Thermo Fisher Scientific, Catalog No.: 4331182). For PLZF measurement, the reagent set used was Assay ID: Hs00957433_m1 (Gene: Zbtb16) (Thermo Fisher Scientific, Catalog No.: 4331182). Measurement results were normalized by the expression level of β-actin. The results are shown in Figure 9. Results are presented as mean ± standard deviation (n = 3).
[0106] Among primary T cells of the adaptive immune system obtained from peripheral blood, CD4 single-positive T cells expressed higher levels of Thpok than CD8 single-positive T cells. Similarly, CD4SP iPSC-T cells expressed higher levels of Thpok than CD8SP iPSC-T cells, suggesting a phenotype related to helper T cells. On the other hand, both CD4SP iPSC-T cells and CD8SP iPSC-T cells expressed PLZF, which is significantly different from primary T cells of the adaptive immune system obtained from peripheral blood, which do not express PLZF at all. This suggests that CD4SP iPSC-T cells and CD8SP iPSC-T cells have a unique innate immune-like phenotype.
[0107] [Expression of Thpok and Runx3 in CD4 Single-Positive Helper T Cells (CD4SP iPSC-T Cells) and CD8 Single-Positive Killer T Cells (CD8SP iPSC-T Cells) Generated from iPS Cells] Thpok is a master transcription factor for helper T cell differentiation and is essential for helper T cell function. Runx3 is a master transcription factor for killer T cell differentiation. According to Example 1, CD4SP iPSC-T cells and CD8 SP iPSC-T cells were isolated from a cell population containing CD4SP iPSC-T cells and CD8 single-positive killer T cells (CD8SP iPSC-T cells) that had been matured without the use of feeder cells by DLL4-Fc / retronectin switching in the coating of cell culture plates. We also isolated CD4 single-positive helper T cells (ATO-CD4SP iPSC-T cells) and CD8 single-positive killer T cells (ATO-CD8SP iPSC-T cells) from T cells generated from iPS cells by culturing them in an artificial thymic organ (ATO, see Non-Patent Document 6) on feeder cells. Furthermore, we isolated CD4 single-positive helper T cells and CD8 single-positive killer T cells from primary T cells derived from peripheral blood of healthy individuals. Total mRNA was isolated from these cells immediately after maturation, and Thpok and Runx3 expression was measured by TaqMan qPCR (quantitative PCR). Thpok was measured using the reagent set Assay ID: Hs00757087_g1 (Gene: Zbtb7b) (Thermo Fisher Scientific, Catalog No.: 4331182). Runx3 was measured using the following reagent set: Assay ID: Hs01091094_m1 (Gene: Runx3) (Thermo Fisher Scientific, Catalog No.: 4331182). Measurement results were normalized by the expression level of β-actin. The results are shown in Figure 10. Results are presented as mean ± standard error (n = 3).
[0108] CD4SP iPSC-T cells matured without feeder cells, as well as ATO-CD4SP iPSC-T cells and CD4 single-positive helper T cells derived from peripheral blood-derived primary T cells, showed statistically significantly higher Thpok expression levels than their respective corresponding CD8 single-positive killer T cells, suggesting a helper T cell-related phenotype. Furthermore, Thpok expression levels in feeder-free CD4SP iPSC-T cells were significantly higher than those in peripheral blood-derived CD4 single-positive helper T cells, suggesting enhanced helper T cell function. On the other hand, no significant difference in Runx3 expression was observed between CD4 single-positive helper T cells and CD8 single-positive killer T cells.
[0109] [Proliferation of CD4 single-positive helper T cells (CD4SP iPSC-T cells) and CD8 single-positive killer T cells (CD8SP iPSC-T cells) generated from iPS cells] According to Example 1, CD4SP iPSC-T cells and CD8 single-positive killer T cells (CD8SP iPSC-T cells) were matured without the use of feeder cells by DLL4-Fc / retronectin switching in the coating of cell culture plates. From this cell population, CD4SP iPSC-T cells and CD8SP iPSC-T cells were isolated. In addition, CD4 single-positive helper T cells (ATO-CD4SP iPSC-T cells) and CD8 single-positive killer T cells (ATO-CD8SP iPSC-T cells) were isolated from T cells generated from iPS cells by culturing them in an artificial thymic organ (ATO, see Non-Patent Document 6) on feeder cells. Furthermore, CD4 single-positive helper T cells and CD8 single-positive killer T cells were isolated from primary T cells derived from peripheral blood of healthy individuals. These cells were stimulated with anti-CD3 antibody (1 μg / mL) immobilized on a cell culture plate in the presence of IL-7 (5 ng / mL), IL-12 (50 ng / mL), IL-15 (5 ng / mL), IL-18 (50 ng / mL), and IL-21 (20 ng / mL), and the cell count was measured 14 days later. The cell count was determined as viable cells by trypan blue staining.
[0110] The proliferation rates of these cells are shown in Figure 11. In Figure 11, dots representing pairs of independent experiments (CD4 and CD8) are connected by lines. The proliferation rate of feeder-free CD4SP iPSC-T cells was significantly higher than that of feeder-free CD8SP iPSC-T cells. Conversely, in peripheral blood-derived primary T cells, the proliferation rate of CD8 single-positive killer T cells was significantly higher than that of CD4 single-positive helper T cells. The proliferation rates of ATO-CD4SP iPSC-T cells and ATO-CD8SP iPSC-T cells were nearly identical.
[0111] Analysis of naive and adaptive immune markers expressed by CD4 single-positive helper T cells (CD4SP iPSC-T cells) and CD8 single-positive killer T cells (CD8SP iPSC-T cells) generated from iPS cells after feeder-free expansion. Cell populations containing CD4SP iPSC-T cells and CD8SPC iPSC-T cells generated according to Example 1 were expanded without the use of feeder cells. Expansion was performed as follows. First, an anti-CD3 antibody (OKT3) diluted to 1 μg / mL with PBS was added to each well of a 96-well flat-bottom cell culture plate. The plate was then left to stand overnight at 4°C and washed once with PBS to prepare an anti-CD3 antibody-coated cell culture plate. Next, the cell population was suspended in αMEM containing 20% fetal bovine serum, PSG (penicillin-streptomycin-L-glutamine) solution (100x), ITS (insulin-transferrin-sodium selenite) supplement (100x), 2-phospho-L-ascorbic acid (50 μg / mL), human recombinant IL-7 (5 ng / mL), human recombinant IL-15 (5 ng / mL), human recombinant IL-21 (20 ng / mL), IL-12 (50 ng / mL), and IL-18 (50 ng / mL), and added (2 x 10 4 After incubation at 37°C and 5% CO 2 The cells were cultured for 16 hours under the same conditions. After that, the cells were transferred to a cell culture plate that had not been coated with anti-CD3 antibody. After that, half of the culture medium was replaced with fresh medium every three days, and the cells were cultured at 37°C, 5% CO 2 The culture medium used for the medium replacement was αMEM containing 20% fetal bovine serum, PSG solution (100x), ITS supplement (100x), 2-phospho-L-ascorbic acid (50 μg / mL), human recombinant IL-7 (5 ng / mL), and human recombinant IL-15 (5 ng / mL).
[0112] Cell surface markers were analyzed by flow cytometry for post-expansion cell populations and compared with pre-expansion cell populations. Fresh human peripheral blood mononuclear cells (PBMCs) were also analyzed by flow cytometry. PBMCs were prepared using lymphocyte separation tubes (Greiner Bio-One) according to the manufacturer's instructions. The results are shown in Figure 12. CD2 and CD5 are established adaptive immune markers expressed by all T cells. Meanwhile, CD28 is a naive immune marker. After feeder-free expansion, Figure 12 shows that CD4SP iPSC-T cells expressed and maintained adaptive and naive immune markers even after expansion, compared with CD8SP iPSC-T cells. Furthermore, CD5 and CD28 expression in CD4SP iPSC-T cells was comparable to that of fresh PBMCs from healthy individuals, even after expansion. These adaptive immune and naive markers are highly expressed in young T cells with less exhausted traits, and are known to positively correlate with the efficacy of immune cell therapy.
[0113] Cytokine Production by CD4 Single-Positive Helper T Cells (CD4SP iPSC-T Cells) and CD8 Single-Positive Killer T Cells (CD8SP iPSC-T Cells) Prepared from iPSCs. A cell population containing CD4SP iPSC-T cells and CD8SP iPSC-T cells prepared according to Example 1 was retrovirally transduced with an anti-CD19 CAR (anti-CD19 CAR-IRES-EGFR) as previously reported (Ueda T, et al. Nat Biomed Eng. 2023;7:24-37). EGFR expression in the resulting cells was analyzed by flow cytometry. Figure 13A shows a histogram of EGFR expression, confirming EGFR expression in both CD4SP iPSC-T cells and CD8SP iPSC-T cells. Anti-CD19 CAR-IRES-EGFR-transduced CD4SP iPSC-T cells and CD8SP iPSC-T cells were isolated by flow cytometry (FACSAria, Becton-Dixon) and 1 × 10 4 The cells were cultured in a CD19-positive human pre-B cell leukemia cell line, Nalm6 (5 × 10 4 ) and 37°C, 5% CO 2 The CD4SP iPSC-T cells were co-cultured for 24 hours under a 5% COG / IL-14 environment. The co-culture was performed in αMEM (200 μL) containing 15% fetal bovine serum, PSG, and ITS in the presence of IL-7 (5 ng / mL) and IL-15 (5 ng / mL). After the culture, the cytokine levels (IFN-γ, IL-2, and TNFα) in the culture supernatant were measured using the BD® Cytometric Bead Array Human Th1 / Th2 / Th17 Cytokine Kit (BD Biosciences). The results are shown in Figure 13B. CD4SP iPSC-T cells were shown to produce higher levels of IFN-γ, IL-2, and TNFα than CD8SP iPSC-T cells. These cytokines not only exhibit direct antitumor activity but are also known to modify the immunosuppressive tumor microenvironment. Therefore, the CD4SP iPSC-T cells generated according to Example 1 are suggested to be useful for cancer immunotherapy.
[0114] [Cancer cell-killing activity of CD4 single-positive helper T cells (CD4SP iPSC-T cells) and CD8 single-positive killer T cells (CD8SP iPSC-T cells) generated from iPS cells] CD4SP iPSC-T cells and CD8SP iPSC-T cells were isolated by flow cytometry (FACSAria, Becton-Dixon) from the cell population containing CD4SP iPSC-T cells generated according to Example 1. These cells were used as effector cells (E) and as target cells (T) to examine the killing activity of the pre-B cell leukemia cell line Nalm6. CD4SP iPSC-T cells or CD8SP iPSC-T cells were cultured with Nalm6 cells in αMEM containing 15% fetal bovine serum, PSG, and ITS in the presence of IL-7 (5 ng / mL) and IL-15 (5 ng / mL) at 37°C and 5% CO. 2 The co-culture was initiated at an E / T ratio of 0.25, and on day 3, Nalm6 cells were added and continued at an E / T ratio of 0.125. On day 7, cytotoxicity against Nalm6 cells and proliferation of CD4SP iPSC-T cells or CD8SP iPSC-T cells were measured by FACS. The results are shown in Figure 14. On day 7, CD4SP iPSC-T cells were superior to CD8SP iPSC-T cells in proliferation and killing activity against Nalm6 cells.
[0115] [Effects of IL-7 and IL-15 on the cytotoxic activity of CD4 single-positive helper T cells (CD4SP iPSC-T cells) and CD8 single-positive killer T cells (CD8SP iPSC-T cells) generated from iPS cells] CD4SP iPSC-T cells and CD8SP iPSC-T cells were isolated from the cell population containing CD4SP iPSC-T cells and CD8SP iPSC-T cells generated according to Example 1. These cells were used as effector cells (E) and the effects of IL-7 and IL-15 on the killing activity of the pre-B cell leukemia cell line Nalm6 as target cells (T) were examined. CD4SP iPSC-T cells or CD8SP iPSC-T cells (4 x 10 3 Nalm6 cells (2 × 10 cells) were cultured in αMEM containing 15% fetal bovine serum, PSG, and ITS in the presence or absence of IL-7 (5 ng / mL) and IL-15 (5 ng / mL). 4 ) and 37°C, 5% CO 2 On the third day of co-culture, Nalm6 cells (2 × 10 4 (1000 cells) were added and coculture was continued. The number of viable Nalm6 cells was measured by FACS at the start of coculture and on days 3 and 7 of coculture. The results are shown in Figure 15. In the presence of IL-15 alone and in the presence of IL-7 and IL-15, the killing activity of CD4SP iPSC-T cells and CD8SP iPSC-T cells against Nalm6 cells was nearly equivalent. On the other hand, in the presence of serum alone (without IL-7 or IL-15) and IL-7 alone, the cell killing activity of CD4SP iPSC-T cells was stronger than that of CD8SP iPSC-T cells. In other words, the cytotoxic activity of CD4SP iPSC-T cells was less dependent on the homeostatic cytokines IL-7 and IL-15 than that of CD8SP iPSC-T cells. This is a necessary requirement for T cells to maintain their activity even in tumor microenvironments where the supply of homeostatic cytokines is insufficient.
[0116] Cytotoxic activity against cancer cells of CD4 single-positive helper T cells (CD4SP iPSC-T cells) and CD8 single-positive killer T cells (CD8SP iPSC-T cells) generated from iPS cells, T cells generated from iPS cells by culture in an artificial thymic organ (ATO, see Non-Patent Document 6) (ATO-iPSC-T cells), and primary T cells derived from healthy individuals. CD4SP iPSC-T cells and CD8SP iPSC-T cells were generated according to Example 1 and expanded without feeder cells (modified feeder-free iPSC-T cells). Expansion was performed according to Example 5. ATO-iPSC-T cells and primary T cells derived from healthy individuals were expanded in the same manner. After expansion, these T cells were retrovirally transduced with anti-CD19 CAR (anti-CD19 CAR-IRES-EGFR) as previously reported (Ueda T, et al. Nat Biomed Eng. 2023; 7:24-37). CD4SP T cells and CD8SP T cells expressing anti-CD19 CAR (EGFR-positive) were isolated by flow cytometry (FACSAria, Becton-Dixon). These T cells (4 × 10 3 ) were used as effector cells (E), and CD19-positive human pre-B cell leukemia cell line Nalm6 or CD19-negative human leukemia cell line K562 (2 × 10 4 ) and 37°C, 5% CO 2 On the third day of co-culture, target cells (2 × 10 4(individuals) were added and co-culture was continued, and on day 7 of co-culture, proliferation of the cancer cells (target cells) was measured by FACS. Co-culture was performed in the absence of cytokines, in the presence of IL-7 (5 ng / mL), IL-15 (5 ng / mL), or IL-7 and IL-15, using αMEM containing 15% fetal bovine serum, PSG, and ITS. After co-culture was completed, the number of viable Nalm6 and K562 cells was measured by FACS. The results when Nalm6 cells were used as target cells are shown in Figure 16A, and the results when K562 cells were used as target cells are shown in Figure 16B.
[0117] The modified feeder-free iPSC-T cells exhibited cytotoxic activity against CD19-positive Nalm6 cells similar to that of ATO-iPSC-T cells. Both the modified feeder-free iPSC-T cells and CD4SP T cells derived from ATO-iPSC-T cells exhibited superior target-specific cytotoxic activity to CD8SP T cells. However, in vitro cytotoxic activity of primary T cells was observed exclusively in CD8SP T cells. Unlike CD8SP iPSC-T cells generated as previously reported (Maeda T, et al. Cancer Res. 2016; 76:6839-6850, Kawai Y, et al. Molecular Therapy. 2021; 29:3027-3041), the modified feeder-free iPSC-T cells, ATO-iPSC-T cells, and primary T cells did not exhibit NK (natural killer) activity against NK-sensitive K562 cells. This suggests that, unlike the T cells generated as previously reported, the risk of graft-versus-host disease due to unintended NK activity is low.
[0118] Effects of iPS cell-derived CD4 single positive helper T cells (CD4SP iPSC-T cells) and CD8 single positive killer T cells (CD8SP iPSC-T cells) in mice transplanted with the human pre-B cell leukemia cell line Nalm6: Pharmacokinetics of Nalm6 and impact on mouse survival. NOD-SCID IL2Rgc null(NSG) mice were transfected with luciferase-expressing human pre-B cell leukemia cell line Nalm6 (2 × 10 per mouse). 5 On day 2, CD4SP iPSC-T cells or CD8SP iPSC-T cells (5 × 10 per mouse) that had been prepared according to Example 1, expanded without feeder cells, and transfected with anti-CD19 CAR were intravenously transplanted. 6 (100 pieces) were administered intravenously. As a control, the culture medium without T cells was administered intravenously. Luciferase luminescence was then observed by in vivo imaging on days 14, 21, and 28. The results are shown in Figure 17A. In the control group, luciferase luminescence increased over time, indicating the establishment and proliferation of transplanted Nalm6 cells. On the other hand, in the CD4SP iPSC-T cell-administered group, luciferase luminescence levels were lower than in the control group, demonstrating the suppression of Nalm6 proliferation. The Nalm6 proliferation-suppressing effect in the CD4SP iPSC-T cell-administered group was shown to be stronger than that in the CD8SP iPSC-T cell-administered group.
[0119] Figure 17B shows the Kaplan-Meier survival curve. CD4SP iPSC-T cells showed significantly improved survival rates compared to CD8SP iPSC-T cells, demonstrating their superior in vivo tumor suppression effects. Statistical significance was analyzed using the log-rank test according to the Maltel-Cox method ( * P=0.0194).
[0120] [Preparation of CD4 single-positive helper T cells from iPS cells (Method 2)] iPS cells were prepared from CD3-positive T cells isolated from human peripheral blood using the method described in Non-Patent Document 3. A pan T cell isolation kit (Pan T Cell Isolation Kit, Miltenyi Biotec, catalog number: 130-096-535) was used to isolate the T cells.
[0121] (Day 0) To each well of a 48-well cell culture plate (Corning, catalog number: 3548), 150 μL of a DLL4-Fc solution (Shino Bio, catalog number: 10171-H02H) diluted to 5 μg / mL with phosphate-buffered saline (PBS) was added and the plate was left standing at 4°C overnight to coat the plate with human DLL4-Fc. DLL4-Fc is a recombinant protein in which the Fc domain of human IgG1 is attached to the C-terminus of the extracellular domain (residues 1 to 524) of human DLL4 (Delta-Like Protein 4), and it was used as a T cell differentiation inducer.
[0122] Days 1 to 21: Step (1) (Day 1) Embryoid bodies formed by 14 days of suspension culture of iPS cells were collected and dispersed into single cells by six cycles of aspirating and discharging using a syringe equipped with a 21-gauge needle. Cell debris was then removed using a cell strainer. The resulting cells were suspended in T cell differentiation medium. The DLL4-Fc-coated cell culture plate was washed once with 1 mL / well of PBS, and 500 μL / well of T cell differentiation medium was added. 2 × 10 3 The cell suspension containing 100 cells was added at 500 μL / well. The cells added to the cell culture plate were incubated at 37°C, 5% CO while replacing half of the culture medium with fresh T cell differentiation medium every 2 to 3 days. 2 It was cultivated under the environment.
[0123] The T cell differentiation culture medium used was αMEM (Thermo Fisher Scientific) containing 15% fetal bovine serum (Corning), ITS (insulin-transferrin-sodium selenite) supplement (100x), 2-mercaptoethanol (final concentration 55 μM, Thermo Fisher Scientific), the GSK-3 inhibitor CHIR-99021 (1 μM, Wako), 2-phospho-L-ascorbic acid (final concentration 50 μg / mL), GlutaMAX (100x, Registered Trademark), human recombinant SCF (final concentration 50 ng / mL), human recombinant TPO (final concentration 50 ng / mL), human recombinant IL-7 (final concentration 50 ng / mL), human recombinant Flt3L (final concentration 50 ng / mL), human recombinant SDF-1α (final concentration 10 nM, PeproTech), and the p38 inhibitor SB203580 (final concentration 15 μM, Tocris Bioscience).
[0124] (Day 21) The obtained cells were analyzed by flow cytometry, and it was confirmed that the cells differentiated from the iPS cells were CD4 / CD8 double positive.
[0125] Days 22 to 23: Step (2) (Day 22) PBS containing 5 μg / mL RetroNectin (RetroNectin, registered trademark, Takara Bio) was added to each well of a new 48-well cell culture plate and left to stand at 37°C for 2 hours to coat the cell culture plate with RetroNectin. RetroNectin was used as a cell adhesion factor.
[0126] After washing the RetroNectin-coated cell culture plate once with 1 mL / well of PBS, the CD4 / CD8 double-positive cells were added and stimulated with 1 μg / mL of an anti-CD3 agonist antibody (OKT3) for 2 days. Culture medium was αMEM supplemented with 15% fetal bovine serum, ITS (insulin-transferrin-sodium selenite) supplement (100x), GlutaMAX (100x), 2-phospho-L-ascorbic acid (50 μg / mL), PSG (penicillin-streptomycin-L-glutamine) solution (100x, Sigma-Aldrich), the GSK-3 inhibitor CHIR-99021 (1 μM, Wako), IL-7 (50 ng / mL), SDF-1α (10 nM), and the p38 inhibitor SB203580 (10 mM).
[0127] Day 24 onwards (Days 27 to 34): Step (3) (Day 24) The cells obtained in step (2) were collected, washed and then seeded onto a newly prepared cell culture plate coated with RetroNectin. The cells were cultured in a culture medium with the same composition as that used in step (2) (but without anti-CD3 antibody) at 37°C and 5% CO for 4 to 11 days. 2 It was cultivated under the environment.
[0128] Flow cytometric analysis of the cells obtained in step (3) confirmed the presence of CD4 single-positive helper T cells (Figure 18A). Further analysis of the CD4 single-positive helper T cell subset by flow cytometry showed high expression of CD5 and TCR α / β chains, but almost no expression of CD1a (Figure 18B).
[0129] Effect of the GSK-3 inhibitor CHIR-99021 on the generation of CD4 single-positive helper T cells and CD8 single-positive killer T cells. The GSK-3 inhibitor CHIR-99021 functions as a Wnt pathway activator. In steps (1) to (3) of Example 17, the generation of CD4 single-positive helper T cells from hematopoietic stem cells derived from iPS cells was examined in the presence or absence of CHIR-99021. The results of flow cytometry analysis of the obtained cells are shown in Figure 19. As a result, the proportion of CD4 single-positive helper T cells was 3.08% in the absence of CHIR-99021, but 10.3% in the presence of CHIR-99021, demonstrating the effect of adding CHIR-99021 on the generation of CD4 single-positive helper T cells.
[0130] Next, the abundance and cell yield of CD4 single-positive helper T cells and CD8 single-positive killer T cells were examined in the presence or absence of CHIR-99021 in steps (1) to (3) of Example 17. The results are shown in Figures 20A and 20B. CHIR-99021 significantly increased the abundance of CD4 single-positive helper T cells (Figure 20B), but significantly decreased the abundance of CD8 single-positive killer T cells (Figure 20A). Meanwhile, cell yield increased for both CD4 single-positive helper T cells and CD8 single-positive killer T cells. Statistical analysis was performed using a paired t-test.
[0131] [CD4 and CD8 Expression After Expansion of CD4 and CD8 Single-Positive T Cells Obtained in the Presence of CHIR-99021] According to Example 17, mature T cells generated from iPS cell-derived hematopoietic stem cells in the presence of CHIR-99021 were analyzed by flow cytometry for CD4 and CD8 expression. The results are shown in Figure 21 (Before Expansion). These results confirmed the generation of CD4 single-positive T cells and CD8 single-positive T cells. These CD4 and CD8 single-positive T cells were sorted by flow cytometry and expanded for 14 days using anti-CD3 and anti-CD28 antibody-conjugated beads (Dynabeads®). CD4 and CD8 expression was then analyzed by flow cytometry. The results are shown in Figure 21 (After Sorting and Expansion). These results demonstrate that both the obtained CD4 single-positive T cells and CD8 single-positive T cells can be expanded and maintain co-receptor expression.
[0132] CD40L Expression by TCR Stimulation of CD4 Single Positive Helper T Cells (CD4SP iPSC-T Cells) Generated from iPS Cells in the Presence of CHIR-99021: A cell population containing CD4SP iPSC-T cells was generated from iPS cells according to Example 17. CD40L expression in this cell population was analyzed by flow cytometry before and after TCR stimulation with an anti-CD3 agonist antibody coated on a cell culture plate in the presence of IL-7, IL-12, IL-15, IL-18, and IL-21. The analysis results are shown in Figure 22. CD40L-expressing cells increased from 2.18% to 62.5% upon TCR stimulation. Comparison of the percentage of CD40L-expressing cells before and after TCR stimulation in three independent experiments demonstrated that TCR stimulation significantly increased the number of CD40L-expressing cells. These results suggest that the CD4SP iPSC-T cells prepared according to Example 17 can fully function as helper T cells upon TCR stimulation. Statistical analysis was performed using a paired t-test.
[0133] Cytokine Production by CD4 Single Positive Helper T Cells (CD4SP iPSC-T Cells) and CD8 Single Positive Killer T Cells (CD8SP iPSC-T Cells) Generated from iPS Cells in the Presence of CHIR-99021: CD4SP iPSC-T cells and CD8SP iPSC-T cells generated according to Example 17 were treated with phorbol 12-myristate 13-acetate (PMA) and ionomycin in the presence of monensin for 4 hours, and then stained with anti-IFN-γ and anti-IL-2 antibodies to measure cytokine production. The results are shown in Figure 23. CD4SP iPSC-T cells were shown to produce higher levels of IFN-γ and IL-2 than CD8SP iPSC-T cells. These cytokines not only exhibit direct antitumor activity but are also known to modify the immunosuppressive tumor microenvironment. Therefore, it is suggested that the CD4SP iPSC-T cells prepared according to Example 17 are useful for cancer immunotherapy.
[0134] [Transduction of anti-CD19 CAR into CD4 single-positive helper T cells (CD4SP iPSC-T cells) and CD8 single-positive killer T cells (CD8SP iPSC-T cells) generated from iPS cells in the presence of CHIR-99021] Anti-CD19 CAR (anti-CD19 CAR-4-1BB-CD3zeta) was retrovirally transduced into CD4 single-positive helper T cells and CD8 single-positive killer T cells generated according to Example 17, as previously reported (Ueda T, et al. Nat Biomed Eng. 2023; 7:24-37). Flow cytometric analysis of anti-CD19 CAR expression in the resulting cells is shown in Figure 24. It was confirmed that anti-CD19 CAR was expressed to similar levels in both CD4SP iPSC-T cells and CD8SP iPSC-T cells.
[0135] Cancer cell-killing activity of CD4 single-positive helper T cells (CD4SP iPSC-T cells) and CD8 single-positive killer T cells (CD8SP iPSC-T cells) generated from iPS cells in the presence of CHIR-99021. CD4SP iPSC-T cells and CD8SP iPSC-T cells generated according to Example 17 were transfected with anti-CD19 CAR (anti-CD19 CAR-4-1BB-CD3zeta) to serve as effector cells (E). The CD19-positive human pre-B cell leukemia cell line Nalm6 was used as target cells (T), and the killing activity of the effector cells against the target cells was examined. Effector cell (E):target cell (T) ratios were varied to 1:4, 1:2, 1:1, 2:1, and 4:1. After one day, the remaining target cells (Nalm6) were counted by flow cytometry. The results are shown in Figure 25. The cell-killing effect was observed in both CD4SP iPSC-T cells and CD8SP iPSC-T cells.
Claims
1. A method for producing a cell population containing CD4 single positive and CD8 negative helper T cells, comprising: (1) a step of culturing hematopoietic stem cells, whose differentiation has been induced from pluripotent stem cells, in the presence of a T cell differentiation inducer; (2) a step of culturing the cells obtained in step (1) in the presence of a T cell differentiation inducer and a cell adhesion factor; and (3) a step of culturing the cells obtained in step (2) in the presence of the cell adhesion factor but in the absence of the T cell differentiation inducer.
2. The method according to claim 1, wherein the cell culture in steps (1), (2) and (3) is carried out in the presence of a Wnt / β-catenin pathway activator.
3. The method according to claim 1 or 2, further comprising a step of confirming that the cells obtained in step (1) contain T cell precursors that are CD3, CD1a and CD5 positive.
4. The method according to claim 1 or 2, further comprising the step of confirming that the cells obtained in step (2) contain T cells that are CD3 positive and CD4 / CD8 double positive.
5. The method according to claim 4, wherein the CD3 positive and CD4 / CD8 double positive T cells are further CD5 and CD1a positive.
6. The method according to claim 1 or 2, wherein the cells obtained in step (3) are mature helper T cells which are CD1a and CD8 negative and CD5 positive and CD4 single positive, or a mixture of the mature helper T cells and mature killer T cells which are CD5 and CD8 positive and CD1a and CD4 negative.
7. The method according to claim 1 or 2, further comprising the step of confirming that the cells obtained in step (3) contain T cells that highly express CD28.
8. The method according to claim 7, wherein the CD28 expression level of the T cells highly expressing CD28 is equivalent to the CD28 expression level of T cells present in human peripheral blood.
9. A method for producing a cell population containing CD4 single positive and CD8 negative helper T cells, comprising: (1) a step of culturing hematopoietic stem cells induced to differentiate from pluripotent stem cells in the presence of a T cell differentiation inducer and a Wnt / β-catenin pathway activator; (2) a step of culturing the cells obtained in step (1) in the presence of a cell adhesion factor, a Wnt pathway activator and an anti-CD3 antibody, but in the absence of a T cell differentiation inducer; and (3) a step of culturing the cells obtained in step (2) in the presence of a cell adhesion factor and a Wnt pathway activator, but in the absence of a T cell differentiation inducer and an anti-CD3 antibody.
10. The method according to claim 9, wherein the cells obtained in step (3) are a mixture of mature helper T cells which are CD1a and CD8 negative, and CD5 positive and CD4 single positive, and mature killer T cells which are CD5 and CD8 positive, and CD1a and CD4 negative.
11. The method of claim 1 or 9, wherein the T cell differentiation inducer is a Notch ligand.
12. The method of claim 11, wherein the Notch ligand is DLL4 or DLL4-Fc.
13. The method of claim 1 or 9, wherein the cell adhesion factor is fibronectin or a fragment thereof, or Retronectin (registered trademark).
14. The method of claim 2 or 9, wherein the Wnt pathway activator is a GSK-3 inhibitor.
15. The method of claim 14, wherein the GSK-3 inhibitor is CHIR-99021.
16. The method according to claim 1 or 9, wherein the T cell differentiation inducer and the cell adhesion factor are present by coating on a cell culture substrate.
17. The method of claim 16, wherein the cell culture substrate is a cell culture bead or a cell culture plate.
18. The method according to claim 1 or 2, wherein the cell culture in steps (1) and (2) is carried out in the presence of IL-7 and FLT3L.
19. The method according to claim 1 or 2, wherein the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, and SDF-1α and / or a p38 inhibitor.
20. The method according to claim 1 or 2, wherein the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, SDF-1α and a p38 inhibitor.
21. The method according to claim 1 or 2, wherein the cell culture in steps (1) and (2) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, SDF-1α, a p38 inhibitor and SCF.
22. The method according to claim 1 or 2, wherein the cell culture in step (3) is carried out in the presence of IL-7.
23. The method according to claim 1 or 2, wherein the cell culture in step (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, and an SDF-1α and / or p38 inhibitor.
24. The method according to claim 1 or 2, wherein the cell culture in step (3) is carried out in the presence of IL-7, SDF-1α and a p38 inhibitor.
25. The method according to claim 1 or 2, wherein the cell culture in step (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, SDF-1α, a p38 inhibitor and SCF.
26. The method according to claim 1 or 2, wherein the cell culture in steps (1) and (2) is carried out while maintaining the cell density at subconfluent.
27. The method according to claim 9, wherein the cell culture in step (1) is carried out in the presence of IL-7, FLT3L, 2-phospho-L-ascorbic acid, SDF-1α, a p38 inhibitor, SCF and TPO.
28. The method according to claim 9, wherein the cell culture in steps (2) and (3) is carried out in the presence of IL-7, 2-phospho-L-ascorbic acid, SDF-1α and a p38 inhibitor.
29. The method of claim 1 or 9, wherein the pluripotent stem cells are human iPS cells.
30. The method of claim 29, wherein the human iPS cells are human peripheral blood mononuclear cells depleted of B cells and T cells or iPS cells reprogrammed from T cells.
31. A pharmaceutical comprising a cell population produced by the method of claim 1 or 9.
32. The pharmaceutical composition according to claim 31 for use in the prevention or treatment of cancer.
33. A method for killing cells expressing a tumor-associated antigen, comprising administering to said patient a cell population produced by the method of claim 1 or 9.
34. A method for preventing or treating cancer in a mammal, comprising administering to said mammal an effective amount of a cell population produced by the method of claim 1 or 9.
35. A method for preventing or treating cancer in a mammal, comprising administering to said mammal an effective amount of the pharmaceutical agent described in claim 31.
36. A method for preventing or treating cancer in a mammal, comprising administering to said mammal an effective amount of the killing agent of claim 33.
37. A preventive or therapeutic agent for cancer in a mammal, comprising a cell population produced by the method according to claim 1 or 9.
38. Cells produced by the method of claim 1 or 9 for use in the prevention or treatment of cancer.
39. Cells produced by the method of claim 1 or 9 for producing a cancer preventive or therapeutic agent.
Citation Information
Patent Citations
Glypican-3-specific antibody and uses thereof
WO2013070468A1
Glypican-3-specific t-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
WO2015173112A1
Method for producing CD8α+β+ cytotoxic t cells
WO2018135646A1
Method for producing helper t cells from pluripotent stem cells
WO2018168829A1
Protein L for the activation and expansion of chimeric antigen receptor-modified immune cells
JP2022501031A
